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Chitosan has been explored as a non-viral vector for gene therapy due to favourable 
characteristics such as good biocompatibility and biodegradability. The aim of this 
thesis was to prepare and characterise chitosan-plasmid DNA (chitosan-pDNA) 
nanoparticles, using 17 different types of chitosan, in order to evaluate which chitosan 
yields the most favourable nanoparticle characteristics in terms of size and zeta 
potential. Also size stability and correlations between chitosan properties such as 
molecular weight (Mw) and degree of deacetylation (DD), and particle properties were 
assessed in this study. Both basic chitosan and chitosan salts and derivatives were 
tested.  
The particles were prepared by complex coacervation. Size and zeta potential of 
particles were determined by dynamic light scattering (DLS) and Laser Doppler 
velocimetry, respectively. Integration of pDNA with chitosan was assessed by agarose 
gel electrophoresis and morphology of prominent samples was observed using field 
emission gun scanning electron microscope (FEG-SEM). With a fixed chitosan to 
pDNA weight ratio 4:1 most chitosan types, excluding carboxymethylchitosan and 
chitosan oligosaccharide, integrated with pDNA to form nanoscale particles. The size of 
the remaining chitosans ranged from approximately 100 nm to 180 nm and the zeta 
potential was relatively stable ranging from +20 to +30 mV. Smallest particles were 
achieved with chitosan 85/25 (101.2 ± 0.9 nm) and chitosan hydrochloride (100.3 ± 1.3 
nm). Statistical analysis indicated that for most samples particle size increased 
significantly during the first week and then remained relatively stable.   
No clear correlations between chitosan and nanoparticle properties were detected. 
However, it appears that high DD and high Mw chitosans yield more stable complexes 
indicated by higher zeta potentials. According to FEG-SEM images particles were 
spherical and their size ranged from 20-200 nm. Smaller particles appeared to have a 
more even structure. In many cases, however, the particle surface was not smooth 
suggesting possible aggregation. Although chitosan 85/25 and chitosan hydrochloride 
yielded good results in terms of size, it was noted by other researchers in the same 
project that functionalisation of the particles failed due to sedimentation. When the 
weight ratio was changed, functionalisation properties improved. Therefore, future 
research should focus on exploring the effects of different chitosan:pDNA weight ratios 
on particle parameters and also functionalisation possibilities should be considered.  
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Kitosaania pidetään kudosyhteensopivuutensa ja biohajoavuutensa ansiosta lupaavana 
biomateriaalina geeniterapeuttisiin sovelluksiin. Tämän työn tavoitteena oli valmistaa 
sekä karakterisoida kitosaani-pDNA-nanopartikkeleita käyttäen 17:ta erilaista 
kitosaanityyppiä. Näin pyrittiin selvittämään, onko eri kitosaanityyppien välillä suuria 
eroja ja mikä kitosaani tuottaa parhaimmat tulokset koskien nanopartikkelien kokoa ja 
zetapotentiaalia. Myös korrelaatiota nanopartikkeliominaisuuksien, kuten koon, sekä 
kitosaaniominaisuuksien, kuten molekyylipainon (Mw) ja deasetylaatioasteen (DD), 
välillä selvitettiin. Lisäksi tutkittiin partikkelikoon pysyvyyttä kahden viikon 
seurantajaksolla.  
Työssä tutkittiin sekä peruskitosaaneja että kitosaanisuoloja ja -johdannaisia. 
Partikkelit valmistettiin kompleksikoaservaatiomenetelmällä. Partikkelikoko mitattiin 
perustuen dynaamiseen valosirontaan ja zetapotentiaali määritettiin Laser Doppler         
-virtaustekniikan avulla. Plasmidi-DNA:n yhdentyminen kitosaaniin todettiin 
agaroosigeelielektroforeesilla, ja lupaavimmat näytteet kuvattiin kenttäpyyhkäisy-
elektronimikroskoopilla (FEG-SEM). Kitosaani-pDNA massasuhteella 4:1 suurin osa 
kitosaaneista muodosti nanopartikkeleita, poikkeuksena karboksyylimetyylikitosaani ja 
kitosaani-oligosakkaridi. Partikkelien koko vaihteli välillä 100-180 nm. Pienimmät 
partikkelit saatiin aikaiseksi kitosaani 85/25:llä ja kitosaanikloridilla (CH HCl). Koot 
keskihajontoineen olivat 101.2 ± 0.9 nm ja 100.3 ± 1.3 nm. Stabiiliutta mittaava 
zetapotentiaali oli yleisesti ottaen vakaa (20-30 mV). Useimpien näytteiden 
partikkelikoko muuttui tilastollisesti merkittävästi ensimmäisen viikon aikana, jonka 
jälkeen koko ei enää muuttunut merkittävästi.  
Selkeitä korrelaatioita kitosaanin ja partikkelien ominaisuuksien välillä ei ollut 
nähtävissä. Kitosaanit, joilla oli suurempi Mw ja DD, johtivat kuitenkin vakaampiin 
komplekseihin, joiden zetapotentiaali oli korkeampi. FEG-SEM-kuvien perusteella 
partikkelit olivat pallomaisia ja niiden koko vaihteli 20 ja 200 nm:n välillä. Pienimmillä 
partikkeleilla oli tasaisempi pintarakenne, kun taas usean isomman partikkelin pinta oli 
raemainen. On mahdollista, että partikkelit aggregoituivat. Vaikka 85/25 ja CH HCl        
-kitosaaneilla saatiin aikaiseksi parhaimmat tulokset koskien partikkelikokoa, ne 
sedimentoituvat jatkokäsiteltäessä. Kun kitosaani-pDNA massasuhdetta muutettiin, 
tulokset paranivat. Näin ollen jatkotutkimuksissa tulisi selvittää eri massasuhteiden 
vaikutus partikkeliominaisuuksiin, sekä myös pohtia funktionalisointimahdollisuuksia.   
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1. INTRODUCTION 
This thesis was conducted at the Department of Biomedical Engineering (TUT) as part 
of an EU project called “NanoEar”. The aim of the project is to develop multifunctional 
nanoparticles in order to treat hearing disorders. At the moment approximately 250 
million people worldwide suffer from hearing loss and deafness. It is estimated that this 
number will increase to 900 million by 2050. Hearing loss or other sensory impairment 
usually leads to a lower quality of life, which is why it is important to find means to 
treat the disorder. Currently, hearing aids such as cochlear implants are used in the 
treatment of inner ear damage. However, new technologies involving nanomedicine are 
emerging. NanoEar is an early stage project exploring the possibilities of 
nanotechnology in inner ear treatment. Nanosize particles interact on the cell level, 
which permits lower drug doses and better targetability. Other important factors related 
to nanoparticles are biodegradability, traceability in vivo and controlled drug release. 
[82] 
A key gene known as Atoh 1 or Math 1 has been identified as one of the main genes 
regulating the differentiation of cochlear hair cells and supporting cells from their 
precursor cells during embryogenesis [82]. Cochlear hair cells have an important role in 
hearing as mechanical oscillations of the hair cells stimulate sensory neurons of the 
cochlear nerve to transmit electrical signals to the brain that is ultimately responsible for 
the hearing sensation [34, p.299-306 and 342]. Thus, the encapsulation of nucleotides 
encoding Atoh 1 in nanostructures could prove useful for the treatment of inner ear 
disorders [82]. Chitosan is one of the most promising biomaterials examined in 
NanoEar and it has been widely studied as a candidate for non-viral gene delivery due 
to favourable characteristics such as biocompatibility and non-toxicity. This study is 
concerned with the preparation and characterisation of chitosan-pDNA nanoparticles 
using different types of chitosans. Also the effect of different material properties on 
particle parameters is explored.  
The thesis consists of two parts: a literature review and an experimental study. 
Theory related to chitosan, gene therapy, nanoparticles, and characterisation techniques 
is reviewed in Chapters 1-5. Chapter 2 discusses the history, chemistry, synthesis, 
properties, and applications of chitosan as a biomaterial. Also the synthesis of chitosan 
salts and derivatives is discussed in detail. Chapter 3 provides an insight to gene 
therapy, which is the field of interest for chitosan-pDNA nanoparticles. Chapter 4 
describes nanoparticle preparation methods with a specific focus on complex 
coacervation, which is the method used in this study. Also particle parameters and 
properties such as size, zeta potential, and transfection efficiency are described and 
discussed in this section. Chapter 5 introduces various characterisation techniques, 
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including dynamic light scattering (DLS) and Laser Doppler velocimetry, for chitosan-
pDNA nanoparticles. Also agarose gel electrophoresis and field emission gun scanning 
electron microscopy are explained. The experimental part (Chapters 6-7) of the thesis 
aims to provide an insight to the practical work concerning this study. Chapter 6 
elaborates the materials, devices and methods that were used in particle preparation. In 
Chapter 7 results are presented and discussed. The results focus mainly on particle size, 
size stability, zeta potential, and correlations between chitosan properties and particle 
parameters. Finally, conclusions are drawn in Chapter 8.             
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2. CHITOSAN 
Chitosan is the second most abundant natural polysaccharide on Earth. Due to 
favourable characteristics such as good biocompatibility, biodegradability, antimicrobial 
activity and chelating abilities, chitosan is used in various fields and numerous 
applications.  
2.1. History and nomenclature of chitin and chitosan 
To better comprehend the following discussion concerning chitin and chitosan, it is 
necessary to briefly introduce the history and nomenclature of these two 
polysaccharides. Chitosan is the partially N-deacetylated derivative of chitin which, 
after cellulose, is the second most abundant biopolymer on Earth [100]. Chitin occurs as 
a structural mucopolysaccharide in a wide range of species. For example, chitin can be 
found in the exoskeletons of arthropods such as crustaceans, as well as in the 
endoskeletons of cephalopods. In addition, chitin is also present in algae and in the cell 
walls of most fungi. Chitosan, on the other hand, is much less abundant in nature and so 
far it has only been found in the cell walls of certain fungal species. [19; 44; 111] 
Chitin was first discovered by French scientist Henri Braconnot during his studies 
on mushroom in 1811. He initially named chitin fungine. [19] Later, in 1823, the term 
chitin was proposed by Odier, who found the same compound in the cuticles of insects. 
The term “chitin” is derived from the Greek word “chiton” signifying nail coat. [102] 
Chitosan, on the other hand, was discovered by C. Rouget in 1859 when he treated 
chitin in boiling and concentrated potassium hydroxide. Rouget named this structure 
“modified chitin”. This chitin-derivative was renamed chitosan by F. Hoppe-Seyler in 
1894. [19; 119] In 1934, the production of chitosan, as well as the preparation of 
chitosan films and fibres was patented [23, p.336-337]. The modern research of chitin 
and chitosan can be considered to have begun in the early 1970s, when it was realised 
that chitin constitutes a significant waste in sea food related processes. Consequently, 
governments even donated grants in order to valorise this substance. [19] Currently 
chitin is mainly used as the raw material for chitosan, whose application fields include 
agriculture, cosmetics, dietetics, pharmacology, gene therapy, and biomaterials, just to 
name a few [19; 102]. Some useful properties of chitosan are the ability to chelate 
harmful metal ions from waste water, to form water clarifying or filtrating membranes, 
as well as to act as an agent in controlled release [23, p.336-337]. 
Despite the colourful nomenclature history of the above-mentioned polysaccharides, 
the terms chitin and chitosan persist in scientific language of today [19]. Even so, the 
distinction between chitin and chitosan remains vague, as the only differentiating 
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feature in their chemical structure appears to be the degree of deacetylation (DD, see 
Section 2.2) [19]. Some sources state that when the DD of chitin is more than 50%, the 
polymer in question is, in fact, chitosan, while a DD less than 50% suggests that the 
material is chitin [99]. In addition, some sources propose that also the solubility of the 
material has to be taken into account for nomenclature purposes. For instance, if the 
substance is soluble in dilute acids, it is usually considered as chitosan. [99; 111] In 
some rare cases, when the degree of acetylation (DA) is 100%, such as in some marine 
diatoms, the term chitan has also been proposed [38; 44].  
2.2. Chemical structure of chitin and chitosan  
Chitin and chitosan can be considered to belong to the family of glycosaminoglycans 
(GAGs); a subcategory of polysaccharides. Among the latter, it appears that GAGs are 
the only polysaccharides that express bioactivity, which make them especially 
interesting when considering medical applications. [19] The relatively high nitrogen 
content (6.9 wt%) of the chitin structure also makes it useful for chelation [38].  
Chitin is a cationic, linear and high molecular weight polysaccharide that consists of 
β(1-4)-linked 2-acetamido-2-deoxy-D-glucose units [23, p.336-337; 102; 111]. This unit 
is often referred to as N-acetyl-D-glucosamine [19; 102]. However, chitin may be 
slightly N-deacetylated depending on its isolation process and therefore some randomly 
distributed D-glucosamine units may remain in its structure. Chitosan is considered as 
an N-deacetylated form of chitin and it is composed of randomly distributed β(1-4)-
linked 2-acetamido-2-deoxy-β-D-glucopyranose and 2-amino-2-deoxy-β-D-
glucopyranose units. [111] The units in both chitin and chitosan are linked together by 
glycosidic bonds [38]. The chemical structures of chitin and chitosan are presented in 
Figure 2.1. The degree of deacetylation (DD) is one way of defining whether the 
structure in question is chitin or chitosan. A majority of D-glucosamine units in the 
material suggests that the substance is chitosan [44].  
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Figure 2.1. a) Chemical structure of chitin and b) protonated chitosan. “A” represents 
the acetylated unit of chitin and “D” the deacetylated unit. [111]   
 
Chitin and chitosan exist in three different polymorphic forms, namely α-, β- and γ-
chitin [5]. These structures form sheets or stacks of essentially linear chitin chains 
running in certain directions, with each individual chain undergoing a full twist every 
10.1-10.5 Å [119]. α-chitin, present in arthropods, fungi or cysts of Entamoea, is the 
most common allomorph and its antiparallel chain alignment allows it to form strong 
interactions with other molecules. These interactions are due to strong intra- and 
intersheet hydrogen bonding in α-chitin. The α-structure is also commonly used for 
preparing chitosan. [51] The structure of γ-chitin, found in cocoon fibers of the Ptinus 
beetle and in the stomach of Loligo squid, resembles that of α-chitin, but with every 
third stack having the opposite direction to the two previous stacks. It has also been 
suggested that the γ-chitin is a distorted form of α- or β-chitin instead of a true third 
polymorphic form. [5] β-chitin, derived from the pen of the Loligo squid, on the other 
hand, is characterised by the parallel arrangement of chitin molecules that causes weak 
intermolecular forces [23, p.336-337; 40]. The β-conformation also exhibits a higher 
reactivity and higher affinity for solvents compared to α-chitin [40]. β-chitin can readily 
and irreversibly be transformed to α-chitin via steam annealing in the swollen state 
without losing its fibrous orientation, although shrinkage may occur in longitudinal 
direction [38]. Due to the different crystalline structure of β-chitin, it proposes an 
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attractive alternative to α-chitin and studies related to its chemistry are steadily 
progressing [51]. 
It should be mentioned that chitosan has three reactive functional groups. These 
include a primary amino group at the C-2 position, as well as a primary and secondary 
hydroxyl group at the C-3 and C-6 positions, respectively [64; 93]. The repeating unit of 
chitosan and its functional groups are illustrated in Figure 2.2. 
  
 
 
Figure 2.2. Repeating structural unit of chitosan showing the functional groups at 
positions C-2 (primary amino group), C-3 (primary hydroxyl group) and C-6 
(secondary hydroxyl group). Modified from [51]. 
 
In contrast to chitosan, chitin has an acetamido group at the C-2 position. This 
acetamido group can be deacetylated to an amino group in order to produce chitosan. It 
should be noted that the chemical structure of cellulose resembles that of chitin, with the 
only difference being that there is a hydroxyl group at the C-2 position of cellulose 
instead of an acetamido group. [102] The main function of chitin, chitosan and cellulose 
is to provide structural support in nature. Due to the many functional groups in chitin 
and chitosan, the polysaccharides can readily be modified. For example, some chemical 
reactions related to chitosan modification are acylation, deacetylation, alkylation, 
hydrolysis of the main chain, Schiff base formation, reductive alkylation, O-
carboxymethylation, N-carboxyalkylation, silylation, and graft copolymerization. [38; 
52; 52].  
2.3. Synthesis of chitin and chitosan 
The main source for commercially available chitosan is chitin which, as mentioned in 
Section 2.1, occurs widely in the lower plant and animal kingdoms. The most common 
source for chitin and chitosan syntheses are arthropod shells of marine crustaceans like 
crabs and shrimps, that are readily available as waste from the seafood processing 
industry. The shells contain approximately 15-40% of α-chitin. Other major constituents 
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of shells are proteins (20-40%) and calcium carbonate (CaCO3) (20-50%). In addition, 
also pigments and other metal salts are present in the shells. [51]  
2.3.1. Synthesis of chitin 
Chitin is insoluble in most common solvents and therefore the solvent extraction 
method is excluded in the isolation of chitin [51]. Two hydrolytic methods have been 
proposed to prepare chitin and chitosan, namely acid hydrolysis (chemical treatment) 
and enzymatic hydrolysis [102]. Even if not soluble in common solvents, chitin is quite 
stable in mild acidic and basic conditions. Chemical chitin isolation essentially involves 
three steps: decalcification, deproteinisation and decolorisation of crustacean shells. 
[102; 111] After these steps, chitin is obtained as the residue after the decomposition of 
the other constituents of the shells [51].  
More specifically, the chemical synthesis of chitin involves treating crustacean 
shells with dilute hydrochloric acid (HCl) at room temperature in order to remove 
calcium carbonate and metal salts. Carbonate ions react with protons to form 
bicarbonate (HCO3¯) and carbonic acid (H2CO3) that are liberated from the solution as 
carbon dioxide (CO2). [51; 111] Deproteinisation is achieved by alkali treatment at high 
temperatures. Decalcified shells are ground and then heated at about 100°C in 1-2 
mol/L sodium hydroxide (NaOH). This step should remove the proteins and possible 
pigments from the shells. In mild conditions proteases can be used to replace the alkali 
treatment. [51] To ensure the removal of organic substances, the HCl and NaOH 
treatments may be repeated a few times. The order of decalcification and 
demineralisation may also be reversed [111]. Some chitin producers use an organic 
solvent to remove pigments and fat from chitin. Upon drying, the alkali treatment 
results in a flake-like chitin with off-to-white colour. [51] A schematic representation 
of chemical chitin and chitosan synthesis is illustrated in Figure 2.3.  
It should be noted that the cost of shellfish waste and therefore also chitin, is 
dependent on the production region, collection costs and other costs. Uncertainties 
relating to chitin production include the quantity of available waste, the waste 
composition, as well as the selling price and market volume for end use. [38] 
2.3.2. Synthesis of chitosan 
Although chitosan can be extracted from certain fungi, it is currently obtained mainly 
by the N-deacetylation of chitin, as this method is presently more convenient and less 
costly [51]. Chitosan can also be reacetylated from highly deacetylated chitosans [111]. 
The N-deacetylation of chitin is based on using highly concentrated aqueous or 
alcoholic alkali, normally sodium or potassium hydroxide (40-50%), at temperatures of 
100-150°C for periods of 1-5 h under heterogeneous conditions [5; 51; 98; 102]. This 
treatment results in approximately 70% deacetylated chitosan [99].  Repeating the 
procedure increases the degree of deacetylation to a certain extent. However, the 
molecular weight of the chitosan decreases with repeated alkali treatment leading to a 
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decrease in chain length. To overcome this problem, the use of sodium thiophenolate 
has been suggested. Sodium thiophenolate protects the polymer chains from degradation 
while simultaneously allowing the catalysis of the reaction. [19] To minimise the 
amount of NaOH used, also the mixing of chitin with NaOH powder (weight ratio 1.5) 
by extrusion at 180°C has been proposed. This method results in highly deacetylated 
and soluble chitosan with only one half of the NaOH needed for the aqueous treatment. 
[98] Figure 2.3 demonstrates the production process of chitosan, whereby the acetamido 
group of chitin is deacetylated to an amino group due to alkali treatment in the last stage 
of the process. 
 
 
 
Figure 2.3. Production process of chitin and chitosan. Modified from [112] and [99].  
 
Chitin and chitosan can also be synthesised by enzymatic hydrolysis. Examples of 
applicable enzymes include chitinases, chitosanases, lyzosomes and/or cellulases. [102; 
121] Enzymatic synthesis usually leads to low molecular weight chitosans (LMWC), or 
chitosan oligosaccharides (COS), that are readily soluble in water due to shorter chain 
lengths and free amino groups in the D-glucosamine units. This is considered as an 
advantage to insoluble chitosan, as it is believed that solubility and low viscosity of the 
COS will increase the use of chitosan in food and biomedical applications. [46] 
Enzymatic hydrolysis of chitin or chitosan is generally preferable to chemical 
hydrolysis associated with toxic compounds, environmental pollution and low 
production yields. However, the high cost of enzymatic hydrolysis restricts its use in 
COS production, although reuse of hydrolytic enzymes can decrease the production 
costs. Chitosan oligosaccharide synthesis can also be carried out using, for example, 
oxidative degradation and ultrasonic degradation. [46] Also physical depolymerisation 
using gamma radiation can be performed [5]. The resulting physical forms after 
chitosan synthesis and processing usually include hydrogels, solutions, and solid state 
forms. Solid forms of chitosan include, for example, powders, flakes, particles, films, 
and fibres [19].   
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2.4. Synthesis of chitosan salts and derivatives 
Although unmodified chitosan has many favourable characteristics such as good 
biocompatibility and low toxicity, its use is still limited by its low solubility at 
physiological pH 7.4. This restricts the use of chitosan in nasal or oral delivery systems. 
Moreover, the rapid adsorption of water and high swelling limit the use of chitosan in 
controlled release systems. [95] Therefore, alternatives such as chitosan derivatives 
have been developed.  Chitosan can be chemically modified due to the functional 
groups in its structure (see Section 2.2). This modification often results in chitosan 
derivatives that aim to have improved properties over native chitosan. The modified 
material may, for example, exhibit a better drug loading capacity and sustained release 
than the basic chitosan. Also the mechanical strength, stimuli sensitivity and solubility 
can be affected. [95] A concrete example of a chitosan derivative is thiolated chitosan, 
which possesses better mucoadhesive properties than basic chitosan as a result of the 
formation of disulfide bonds with subdomains of mucus glycoproteins [91]. Chitosan 
can also be graft-polymerised to produce different chitosan derivatives. Some examples 
of chitosan derivatives are acetylated chitosan, carboxymethylchitosan, thiolated 
chitosan, chitosan oligosaccharides (COS), chitosan glutamate, chitosan acetate, 
chitosan lactate, chitosan hydrochloride, cyclodextrin-linked chitosan, and so on. [95]  
Despite the common use of chitosan salts and derivatives, little comprehensive 
literature exists in this field. Some attempts to gather information about various chitosan 
salts and derivatives and their preparation methods have recently been made by 
Prabaharan. [95]  Nevertheless, numerous chitosan derivatives are uncovered in this 
review. Some information about specific chitosan derivatives can be found in articles, 
though these mainly focus on an application of the material and not the material itself. 
In this thesis, chitosan derivatives such as chitosan acetate, chitosan lactate, chitosan 
hydrochloride, carboxymethylchitosan, chitosan oligosaccharide and chitosan glutamate 
are used. 
2.4.1. Carboxymethylchitosan  
Carboxymethylchitosans (CMCs) are a family of water-soluble chitosans which form 
semipermeable films and membranes [31]. There are various methods for preparing 
CMCs. In N-carboxyalkylation, an acidic group is introduced to the amino group of the 
polymer backbone. Kurita synthesised N-carboxymethylchitosan by adding glyoxylic 
acid (C2H2O3) to a chitosan solution. After that sodium cyanoborohydride was used to 
reduce the Schiff base intermediate. Finally, N-carboxymethyl chitosan was formed. 
[12; 50] This method is illustrated in Figure 2.4. 
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Figure 2.4. Synthesis of N-carboxymethyl chitosan (CMC). [12] 
 
Also other preparation methods for carboxymethylchitosan have been described and 
patented. [31; 41; 108; 117] For example, O-carboxymethylchitosan can be prepared by 
pretreating chitin powder with 50% NaOH solution for 12h at -18°C, and then reacting 
it with monochloroacetic acid in isopropyl alcohol using a condensation reaction. The 
synthesis of O-carboxymethylchitosan is illustrated in Figure 2.5. 
 
Figure 2.5. Synthesis of O-carboxymethylchitosan. [41] 
 
The water-solubility of the resulting CMC is greatly dependent on preparation 
conditions, especially temperature. It seems that higher preparation temperature leads to 
more insoluble CMCs at neutral pH. [41] Recently, Jayakumar et al. have written an 
extensive review concerning novel carboxymethylchitosan derivatives and their 
applications. The nomenclature of carboxymethylchitosans greatly depends on which 
functional group has been altered during preparation. Modifying the amino or hydroxyl 
group results in N-carboxymethyl or O-carboxymethyl chitosan, respectively. It is also 
possible to modify both groups to obtain N,O-carboxymethylchitosan. These CMCs can 
be further modified to include different functional groups. [41] 
2.4.2. Chitosan acetate and chitosan lactate 
Chitosan acetate can be prepared by linking chitosan and acetic acid by electrovalent 
bonding resulting in a salt whose chemical structure is displayed in Figure 2.6a [58]. 
Due to protonation of amine groups (-NH2), the derivative is water-soluble. Chitosan 
acetate is also more stable than chitosan dissolved in acetic acid and also manages to 
retain the original chitosan structure and antibacterial activity [58]. In addition to 
electrovalent bonding, chitosan acetate has also been prepared by spray-drying. In this 
method chitosan powder is dissolved in a small amount of distilled water containing 
acetic acid. Finally, the chitosan acidic solution is sprayed using a spray dryer, and the 
obtained powder is collected and stored in a dessicator containing dry silica gel. [88] 
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Figure 2.6. a) Chemical structure of chitosan acetate [58] and b) chitosan lactate [12]. 
 
Chitosan lactate can be prepared by spray-drying or by adding the minimum amount 
of lactic acid that is capable of dissolving chitosan in an aqueous chitosan and 
propranolol hydrochloride solution [11; 115]. The structure of chitosan lactate is 
represented in Figure 2.6b. Unfortunately, there is a lack of information about chitosan 
lactate as a material. Therefore, more studies and literature concerning the synthesis and 
properties of chitosan lactate are needed.   
2.4.3. Chitosan oligosaccharide 
Chitosan oligosaccharides (COS) are low-molecular-weight chitosans that are usually 
water-soluble. In the case of chitosan bases, the solution viscosity is usually quite high, 
which makes it difficult to prepare high concentration chitosan solutions that can be 
advantageously used in, for example, pharmaceuticals. As a result, chitosan 
oligosaccharides that allow high concentration solutions with small viscosities have 
been prepared. [122]  
There are a number of preparation methods for chitosan oligosaccharides. To 
mention a few, COS can be fabricated by adding chitosan to water containing a 
monobasic acid, such as hydrochloric or lactic acid, in order to prepare an intimate 
chitosan-water mixture that can be treated further with cellulase. Alternatively, the 
glycoside bonds of chitin can be split to reduce the molecular weight as chitin is 
deacetylated. Chitin glycoside linkages can also be cleaved by a dilute acid before 
deacetylation. These two methods include preparation in severe conditions, which may 
adversely influence chitosan properties. It is also difficult to prepare chitosans with an 
arbitrarily reduced molecular weight. COS can also be prepared by introducing chitosan 
to chlorine gas or treating it with aqueous peroxide solution of an aqueous peroboric 
acid solution. Naturally, using a toxic gas is undesirable especially in biomedical 
applications. The peroxide treatment, on the other hand, results in a molecular weight of 
10 000 g/mol at the lowest, and can therefore not be dissolved in water in neutral 
conditions. [122]  
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A microwave-based preparation technique for LMW chitosan oligosaccharides has 
recently been patented. This method involves adding an acid solvent containing an 
electrolyte to chitosan and performing the reaction at 480-800 W for 3-12 minutes. 
After irradiation the solution is cooled down to room temperature and neutralised with 
1-10 M NaOH or KOH to obtain a yellow floc. Thereafter, precipitation, filtering and 
dessiccation is performed to the solution and finally chitosan oligosaccharides are 
obtained. [57] Finally, also enzymatic hydrolysis and other synthetisation techniques for 
COS mentioned in Section 2.3.2 are applicable.  
2.4.4. Chitosan hydrochloride 
Chitosan hydrochloride (chitosan HCl) can be chemically modified from chitosan by 
preparing an aqueous chitosan suspension to pH 4.7 with 1N HCl. Next, the solution is 
filtrated to remove traces of undissolved material and the resulting solution is 
evaporated and a new water-soluble chitosan is formed. [18; 95] 
2.5. Physicochemical properties of chitosan 
The physicochemical properties of chitosan vary greatly depending on the type of 
chitosan, the production process, the natural source and other factors. Important 
chemical characteristics that influence the properties and hence the applications of 
chitosan, include the degree of deacetylation (DD), molecular weight, polydispersity, 
solubility, and charge. [5; 19; 111] These properties are discussed in more detail below. 
2.5.1. Degree of deacetylation 
The degree of deacetylation (DD) of chitosan is more than 50%, which means that the 
majority of the chitosan monomers are in the deacetylated form and possess an amino 
group at the C-2 position instead of an acetamido group (see Section 2.2) [44]. For 
commercial chitosans the DD is usually 70-95%. For medical applications the 
appropriate DD is 70-100%. [5] The DD is an important determinant of, for instance, 
the biocompatibility and solubility of chitosan [99]. It appears that a higher DD is 
characteristic of a higher biocompatibility [35]. Therefore it is important to choose 
chitosans with an appropriate DD for biomedical purposes. The DD can be determined 
using, for example, IR spectroscopy, gel permeation chromatography, UV 
spectrophotometry, 1H-NMR spectroscopy, 13C solid state NMR, acid-base titration 
methods, and near-infrared spectroscopy. It has been proposed that for gene delivery 
purposes the DD should be ≤ 80%, while for drug delivery systems the DD should be 
higher. [5] 
2.5.2. Molecular weight, viscosity and polydispersity 
The molecular weight (Mw) of chitosan ranges from 5 to 2,000 kDa [32; 114]. In some 
chitosan derivatives such as chitosan oligosaccharides, the Mw can be as low as 1.5 kDa 
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[33]. Due to this extensive range of molecular weights, chitosans can be categorised into 
low molecular weight chitosans (LMWC, 5-20 kDa) [60; 124], medium molecular 
weight chitosans (MMWC, ~100 kDa) and high molecular weight chitosans (HMWC  > 
300 kDa) [14]. It has been suggested that the LMWCs express higher bioactivity than 
MMWCs and HMWCs [14]. 
Like most polysaccharides, chitosan is polydisperse with respect to its molecular 
weight. Therefore, the “molecular weight” of a chitosan sample is the average over a 
whole distribution of molecular weights. This average can be calculated using the 
number average molecular weight (Mn) and the weight average molecular weight (Mw). 
The formulae for calculating these averages are given below in Equations 1 and 2. [111] 
ܯ௡ ൌ
∑ ௜ܰ ܯ௜௜
∑ ௜ܰ௜  (1) 
 
ܯ௪ ൌ ∑ ݓ௜ܯ௜௜∑ ݓ௜௜ ൌ
∑ ௜ܰܯ௜ଶ௜
∑ ௜ܰܯ௜௜  
(2) 
Ni is the number of molecules and wi is the weight of molecules with a specific 
molecular weight Mi. 
The molecular weight can be determined using light scattering, viscosimetry or 
chromatography [28, p.6-7; 111]. The viscosity average molecular weight (Mv) for 
chitosan can be determined using the Mark-Houwink equation: 
ሾߟሿ ൌ ܭܯ௩௔ (3) 
where K and a are constants for a given polymer-solvent system [38]. As can be seen 
from Equation 3, the Mark-Houwink equation describes the relationship between 
viscosity and molecular weight. The viscosity of chitosan solutions depends on factors 
such as degree of deacetylation, molecular weight, temperature, pH, ionic strength, and 
concentration. For instance, higher temperatures will generally lead to lower viscosities. 
[96]  
It could be argued that the molecular weight of chitosan depends on the degree of 
deacetylation. A higher DD would therefore imply a smaller Mw as the acetamido 
groups are replaced by amino groups of lower molecular weight. However, this 
relationship between Mw and DD is not very predictable. [49] For gene delivery 
purposes, it has been suggested that the molecular weight should be low (around 10 
kDa) [5]. For drug delivery systems, on the other hand, it has been stated that HMWCs 
are desirable. [5] 
The polymer dispersity of chitosan can be assessed using polydispersity (PD). The 
polydispersity refers to the width of the molecular weight distribution and it is 
calculated by dividing the weight average molecular weight by the number average 
molecular weight (Mw/Mn) [68]. In a polydisperse population Mw > Mn, while in a 
monodisperse molecule the number and weight average molecular weights are equal. 
Polydispersity near 2 is characteristic to a polymer that has been subjected to random 
depolymerisation, while PD below 2 indicates that fractionation has occurred during the 
production process. PD over 2 suggests a wider distribution and perhaps even a mixing 
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of products of different molecular weights to obtain a sample of certain average 
molecular weight. [111] In the literature chitosan has a PD of 1.4-7 depending on DD 
and Mw [54]. In dynamic light scattering (see Section 5.1) the concept of polydispersity 
is used to give an idea about the width of particle size distribution [68]. A polydispersity 
index (PdI) with a maximum of 1 is often used. In the literature, chitosan nanoparticle 
PDIs vary from 0.027-0.6 [63; 66]. 
2.5.3. Solubility and charge 
Chitosan contains amino groups with a pKa value of 6.2-7, and it is considered as a 
strong base [99; 111]. Chitosan is soluble in dilute acidic solutions at a pH below 6. 
Acetic acid, formic acid, and lactic acid can be used to dissolve chitosan. Chitosan is 
also soluble in some dilute inorganic acids such as hydrochloric acid. Chitosan can also 
form water-soluble salts, such as chitosan acetate or chitosan lactate, with some aqueous 
inorganic or organic acids. [32; 93] The solubility of chitosan generally increases as the 
pH decreases.  This is because at a low pH the amino groups of chitosan get protonated 
resulting in a water-soluble cationic polyelectrolyte. [19; 93; 111] In these conditions 
the surface charge of chitosan nanoparticles is positive, allowing it to interact with 
negatively charged surfaces [32]. However, if the pH is more than 6, the amines in 
chitosan become deprotonated and lose their charge, resulting in a neutral insoluble 
polymer. Also precipitation or gelation may occur. The soluble-insoluble transition of 
chitosan occurs at the pKa value when pH is 6-6.5. [111] Figure 2.7 illustrates the 
relationship between solubility and pH of chitosan in water. At the physiological pH 7.4 
chitosan has low solubility in aqueous solutions. To overcome this problem, many 
soluble chitosan derivatives have been developed by modifying the reactive functional 
groups of chitosan (see Sections 2.2 and 2.4) or by depolymerising the chitosan. [5; 
100]  
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Figure 2.7. Chitosan water-solubility vs. pH. FA is the fraction of acetylated units. 
Modified from [112]. 
  
Because the pKa of the amino groups depends on the degree of deacetylation, also 
the solubility of chitosan depends on this parameter as well as the method of 
deacetylation used. Other important factors affecting the solubility of chitosan are, for 
example, temperature, ionic strength, alkali concentration, time of deacetylation, and 
particle size. [19; 93; 111] As a result, it can be stated that the solubility of chitosan is 
quite difficult to control as it depends on so many parameters [93]. 
2.6. Biological properties of chitosan 
Properties such as biocompatibility, non-toxicity and biodegradability make chitosan an 
interesting material for biomedical and pharmaceutical applications [5; 19]. Also 
hypocholesterolemic, antimicrobial, antitumor and antiviral activity has been associated 
with chitosan [5]. The following discussion elaborates some of the before-mentioned 
properties in more detail.  
2.6.1. Biocompatibility and toxicity 
Chitosan is generally considered biocompatible both in vitro and in vivo. This property 
is somewhat attributable to factors such as the natural source, molecular weight, DD and 
especially the preparation method [5]. The lethal dose (LD50) for oral administration of 
chitosan has been reported to be 16 g/kg body weight in rabbits [39] and 10 g/kg body 
weight in mice [5; 19]. The cytocompatibility of chitosan has been reported in vitro with 
epithelial and myocardial cells. In addition, chitosan is cytocompatible with fibroblasts, 
chondrocytes, hepatocytes, and keratinocytes. Although the DD does not affect the 
cytocompatibility of chitosan on fibroblasts and keratinocytes, it does affect the cell 
adhesion in vitro. [13] In general, cell adhesion increases with increasing DD [19]. 
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Chitosan is haemocompatible and it has been reported as a coagulating factor both 
in vivo and in vitro. In vitro chitosan maintains its coagulating properties even in severe 
anticoagulating conditions and in the presence of abnormal activity by platelets. In mice 
the LD50 of directly injected chitosan is 10 mg/day/kg body weight. However, high 
doses (200 mg/kg) have been reported to lead to hemorrhagic pneumonia in dogs. [19] 
The haemostatic properties of chitosan are due to the positive charge that interacts with 
negatively charged erythrocytes [5]. As a whole, chitosan can be regarded as non-toxic 
when administered in appropriate amounts.  
2.6.2. Biodegradability 
Chitosan can be hydrolyzed by enzymes such as chitosanase, glucosaminidase, 
chitobiase and N-acetyl-glucosaminidase [19]. In mammals, various proteases, 
including lysozyme and pepsin, are capable of degrading chitosan in appropriate pH, 
temperature and ionic strength [5; 19; 119]. The degradation leads to non-toxic chitosan 
oligosaccharides of different lengths that can be utilized in glycosaminoglycans and 
glycoproteins. Alternatively, these degradation products may contribute to metabolic 
pathways or simply be excreted. [5] Therefore, chitosan can be considered to be both 
biodegradable and bioresorbable in vivo. 
The rate of degradation of chitosan is very important because it affects the 
biocompatibility of the material. For instance, scaffold degradation should be 
compatible with the rate of new tissue formation or be adequate for the controlled 
release of bioactive molecules. A very fast degradation will lead to an accumulation of 
amino sugars and cause an inflammatory response. Chitosan with low DD induce acute 
inflammatory responses, while high DD chitosans induce a minimal response as they 
degrade more slowly. [5; 19; 119] Also factors such as viscosity, molecular weight and 
crystallinity affect the biodegradability of chitosan. [5; 19] The rate of biodegradation 
can be assessed using for example viscosimetry and NMR spectrometry. [111]  
2.6.3. Antimicrobial activity 
Chitosan possesses antimicriobial activity towards a number of microorganisms such as 
bacteria, yeast, and fungi [5]. The antimicrobial activity of chitosan may be due to the 
interaction of the positively charged chitosan with anionic groups of bacterial cell 
surface. It has been suggested that this interaction creates an impermeable layer around 
the cell, which inhibits the transportation of essential solutes to the cell. Another 
antimicrobial mechanism is related to the inhibition of RNA and protein synthesis by 
permeation of chitosan into the cell nucleus. This mechanism is related to low molecular 
weight chitosans. Chitosan may also act as a chelating agent rendering trace elements, 
metals, and essential nutrients from the microorganism. [5; 30] Factors affecting the 
antibacterial activity of chitosan are DD, molecular weight, pH of the medium, and 
concentration in solution [61].  
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2.7. Medical applications of chitosan 
Chitosan is diversely used in a number of fields such as agriculture, cosmetics, food 
industry, waste water treatment, pharmaceutics, dietetics, and biomedicine. Because this 
thesis concerns gene therapy and chitosan-DNA nanoparticles, only biomedical 
applications are discussed in more detail. Nevertheless, Table 2.1 gives an idea about 
the applications of chitosan in various fields.  
 
Table 2.1. Applications of chitosan. Modified from [28, p.10] and [30]. 
(Bio)medical Cosmetics 
Water 
treatment 
Pulp & paper 
Food 
industry 
gene delivery 
controlled drug release 
tissue engineering 
blood cholesterol control 
contact lenses 
oral hygiene 
wound dressing 
bandages, sponges 
anticoagulant 
antitumor 
nail polish 
moisturiser 
creams 
bath lotions 
toothpaste 
make-up powder 
flocculant 
 chelating 
filtration 
surface treatment 
carbon free copy paper 
photographic paper 
preservation 
dietary 
supplements 
antioxidant 
prebiotics 
 
As can be observed from Table 2.1, the main applications of chitosan in the 
biomedical field are related to gene delivery, wound healing, and tissue engineering. 
These are elaborated further in the following discussion with a specific focus on gene 
and drug delivery. 
2.7.1. Drug and gene delivery systems 
In drug delivery, the drug is usually combined with a polymeric material which protects 
the drug before its therapeutic action as well as delivers the drug to the body. The 
polymeric material should be biocompatible, non-toxic, biodegradable, stable, and 
sterilisable. Chitosan fulfills these requirements and is therefore an important drug 
delivery vehicle that enhances controlled release, drug absorption and bioadhesion. 
Chitosan can be delivered via parenteral, oral, nasal, transdermal, and ocular routes. 
Drug delivery systems of chitosan include nanoparticles, microparticles, hydrogels, 
solutions, films, tablets and so on. The applied system depends on the delivery route. 
For example, for oral delivery tablets, films or capsules may be used, while solutions 
and microspheres may be applied for the parenteral route. [5; 44]  
The ability of chitosan to form drug and gene delivery systems is due to its cationic 
charge that interacts with negatively charged polyanions, such as DNA, in order to form 
polyelectrolyte complexes. Important properties affecting the drug delivery of chitosan 
are DD, Mw, and purity. Chitosans with a lower Mw have shorter chain lengths and are 
therefore more soluble in water at pH 7, which is important in, for example, cosmetics. 
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However, the relation of DD and Mw to chitosan properties is not very clear and their 
role depends very much on the application. Table 2.2 summarises the effect of DD and 
Mw on microspheres. [5] 
 
Table 2.2. Effect of physicochemical properties of chitosan on microsphere properties. 
Modified from [5]. 
Physicochemical property Properties of microsphere 
DD ↑ 
size ↓ 
loading capacity ↓ 
surface roughness ↓ 
swelling ↓ 
Mw ↑ 
sphericity ↑ 
morphology homogeneity ↑ 
release rate ↓ 
  
Relating to gene therapy, chitosan acts as a non-viral vector incorporating pDNA. 
Compared to viral vectors chitosan offers many advantages as it is not prone to 
oncogenic effects, immunological reactions or endogenous recombination. The 
preparation of chitosan-pDNA complexes is also cheaper than the production of viral 
vectors.  The transfection efficiency of chitosan-pDNA complexes is highly dependent 
on the molecular weight. For instance, high Mw chitosans result in very stable 
complexes, but the transfection efficiency of these complexes is low. Therefore, 
LMWCs and chitosan oligomers have been applied in gene delivery. It appears that an 
appropriate balance has to be achieved between the extracellular DNA protection (better 
with high Mw) versus efficient intracellular unpackaging (better with low Mw). Also the 
effect of DD on gene transfection of chitosan-DNA nanoparticles has been studied and 
it appears that a very high DD (over 80%) releases DNA quite slowly. Hence, a DD 
below 80% may facilitate the release of DNA by lowering charge density, accelerating 
the degradation rate and increasing the steric hindrance in complexing with DNA.  [5] 
2.7.2. Wound dressing / healing 
Chitosan activates immunocytes and inflammatory cells such as macrophages and 
fibroblasts, thereby contributing to wound healing. Chitosan also enhances the wound 
healing process by stimulating fibroblast production by affecting the fibroblast growth 
factor (FGF). Chitosan oligo- and monomers are used in wound healing and chitosan 
has also been combined with other materials, such as collagen and glycosaminoglycans, 
to improve its wound healing properties. In addition, antimicrobial agents such as silver 
sulfadiazine and chlorhexidine, have been added to chitosan. [5; 19; 44]  
2.7.3. Tissue engineering 
Tissue engineering (TE) is defined by Williams as the “creation (or formation) of new 
tissue for the therapeutic reconstruction of the human body, by the deliberate and 
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controlled stimulation of selected target cells through a systematic combination of 
molecular and mechanical signals”. Classically, a material such as a scaffold or matrix 
can be used to support, reinforce or organise the regenerating structure. [118] Chitosan 
scaffolds are promising materials for tissue engineering applications because of their 
controlled biodegradability, biocompatibility, low immunogenicity, and porous 
structure. Other advantages of chitosan for TE include facile processing of the material 
into various shapes and forms as well as the maintenance of the structure at pH 7 once 
formed. Some TE applications of chitosan include nerve tubes, film sponges and 
hydrogels. [44]  
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3. GENE THERAPY 
Gene therapy is based on treating inherited or acquired diseases by replacing or 
substituting defective or missing genes, altering the regulation of genes, or by silencing 
undesired gene expression.  [75; 118] In detail, gene delivery refers to incorporating 
genetic material, such as DNA or RNA, directly or indirectly to specific cells, tissues or 
organs of a patient in order to start encoding desired proteins. Gene therapy is currently 
already applied in treating diseases such as AIDS, cystic fibrosis and cancer. [42]  
3.1. Gene delivery 
There are a number of methods used in gene therapy. These can roughly be divided into 
viral and non-viral methods. [126] Viral gene delivery is concerned with delivering 
genetic material via viral vectors such as adenovirus, adenoassociated virus, herpes 
simplex virus, or retrovirus. Non-viral methods can be categorised further into physical 
and chemical delivery systems. Non-viral physical systems include the delivery of 
naked DNA via needle/jet microinjection, hydrodynamic gene transfer, electroporation, 
gene gun, ultrasound, or sonoporation. Non-viral chemical gene delivery, on the other 
hand, relies on the delivery of genetic material via chemical carriers such as cationic 
lipids, cationic polymers, or inorganic nanoparticles. [3; 87; 123; 126]. Figure 3.1 
summarizes the basic delivery methods of gene therapy as they are described in 
literature. 
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Figure 3.1. Basic delivery methods of gene therapy. Figure based on information in [3; 
72; 87; 123; 126].  
 
Despite the method used, numerous requirements have to be met when 
administering genetic material to patients. First, the gene delivery system should not be 
toxic or initiate immune responses. Second, the system should be able to protect the 
genetic material from nuclease degradation and other macromolecule disposal processes 
until it reaches the target site. Usually the target is the nucleus of a specific cell, which 
means that the system should be small enough for cell internalisation. Third, it should 
be possible for cells to take up the delivery system by endocytosis, pinocytosis or 
phagocytosis. Alternatively, the system can pass through transient holes created by 
physical means. Either way, it is important that the system does not transform into 
digestive lysosomes from the endosome. To prevent this, peptides, lipid components or 
osmotic pressure can be used to rupture the endosome. [3; 72] Finally, the system 
should be affordable, biocompatible, and biodegradable. At present, repeated 
administration is also a desired quality in gene therapy. [3] 
Given the extensive list of requirements for gene delivery, it is not surprising that 
there are several obstacles related to this application. Some of these obstacles are 
biological barriers that can roughly be divided into biological extra- and intracellular 
barriers. [3; 92] Extra-cellular obstacles include anatomical features such as the 
epithelium, extra cellular matrix (ECM), and endothelial cell linings that directly 
prohibit the entry of macromolecules to target cells. Intracellular obstacles can be 
classified as enzymatic degradation, encapsulation in endosomes, inefficient cellular 
uptake, and failure of drug-polymer dissociation. [7; 75; 92] 
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3.2. Vectors 
As described earlier, there are currently two main transport channels for exogenous 
DNA delivery to cells: viral and non-viral vectors. Basically, a non-viral vector is 
formed by the incorporation of DNA to a vector material, such as chitosan. The vector 
material may contain functional groups for environmental interactions including the 
promotion of cell binding or the limitation of serum component interaction. Also 
intracellular trafficking agents may be introduced. These serve to ease endosomal 
escape or facilitate nuclear pore trafficking. The vector is introduced to the body by a 
certain delivery method, such as injection. When the vector reaches the target cell, it is 
taken up by endocytosis and an endosome containing the vector is formed. Thereafter, 
endosomal escape occurs and the vector material is released into the cytoplasm of the 
cell. Some of the functional groups may dissociate at this point if they have already 
fulfilled their purpose. Finally, the vector containing the genetic material is transported 
to the nuclear membrane of the cell. The genetic material is released to the nucleus, 
where the desired proteins will be encoded. [3; 17; 72] The basic principle for the 
delivery of a non-viral vector into a cell nucleus is illustrated in Figure 3.2. 
 
Figure 3.2. Vector path in gene delivery. a) DNA is incorporated into a vector 
backbone (green) that may contain functional groups for environmental interactions 
(yellow) and/or intracellular trafficking (red). The intracellular functional groups 
enhance nuclear accumulation by facilitating endosomal escape or nuclear pore 
trafficking. Environmental functional groups may promote specific cell binding or limit 
serum component interaction. b) The vector enters the cell by endocytosis (1) and an 
endosome is formed (2). The vector contents then escape from the endosome in a 
process called endosomal escape (3). Most molecular components are dissociated from 
the vector (4) before it enters the nucleus (5) and releases the genetic material to be 
encoded. Modified from [3; 17; 72].  
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Each vector type and vector subclass beholds its own specific characteristics. Viral 
vectors have been praised for high transfection efficiency in vivo and immunisation. 
However, there are several drawbacks such as toxicity, immunogenicity and 
inflammatory response, related to the use of viral vectors in gene delivery. Also 
insertional mutagenesis can occur. The latter refers to a situation in which the ectopic 
chromosomal fusion of viral DNA disturbs the expression of a tumour-suppressor gene 
or activates oncogenes, resulting in malignant transformation of cells. [75] Although 
some trials in gene therapy have been executed successfully [27; 94], unfortunately at 
least 2 patient deaths related to viral gene therapy have been reported [22; 97]. 
Therefore, it is clear that the use of viral vectors pose a safety concern in gene therapy, 
and it is utterly important to modify viral vectors in such a way that risks are minimised 
or preferably eliminated.  Alternatively, other means to treat patients via gene therapy, 
such as the use of non-viral vectors, can be applied.  
Non-viral vectors usually consist of cationic polymers (polyplexes) or cationic lipids 
(lipoplexes). The cationic charge of these molecules enables the electrostatic interaction 
with negatively charged DNA. As a result, polymer-DNA complexes are formed. 
Although non-viral vectors possess lower transfection efficiencies than viral vectors, 
they are generally less toxic and immunogenic than their viral counterparts. Other 
advantages of non-viral vectors include ease of synthesis and the possibility for 
repeatable administration with minimal host immune response. Large scale production 
is also easier compared to viral vectors and due to the larger size, more DNA can be 
packaged to non-viral carriers. [3; 72; 75]  
The administration of naked DNA can also be considered as non-viral gene delivery. 
However, its use is limited only to tissues that are appropriate for direct injection such 
as skin and muscle. The use of naked DNA is also related to low transfection efficiency, 
as it is exposed to nuclease degradation. Hence, naked DNA cannot be administered 
systematically. [3; 72] Table 3.1 summarises the advantages and drawbacks of viral, 
non-viral and naked DNA gene delivery systems.  
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Table 3.1. Advantages and drawbacks of some delivery systems in gene therapy. 
Adapted from [42]. 
DELIVERY 
SYSTEM 
ADVANTAGES DISADVANTAGES 
Viral 
vectors 
 high transfection rate 
 rapid transcription. 
 toxic 
 immune and inflammatory effects 
 viral wild-type mutations 
 potential oncogenic effects 
 insertional mutagenesis  
 safety issues 
 only small sequences of DNA can be 
inserted  
 poor target-specificity  
 low capacity to incorporate foreign 
DNA sequences to genome. 
Non-viral 
vectors 
 repeated administration 
 minimal host immune 
response  
 targetable 
 stable in storage 
 easy and cheap to 
produce in large 
quantities 
 low immunogenicity 
 protect DNA from 
nuclease degradation. 
 toxicity (cationic lipids) 
 relatively low transfection efficiency 
(cationic lipids) 
 relatively low efficiency (polymers). 
Naked 
DNA 
 can be used for tissues 
that are suitable for 
direct administration, 
such as skin and 
muscle. 
 unsuitable for systemic administration 
 low expression.  
 
As can be seen from the table, the advantages related to non-viral vectors outweigh 
those of viral vectors by far. However, low transfection efficiencies still pose a 
challenge for the consistent use of non-viral vectors.  
3.2.1. Chitosan as a non-viral vector 
Mumper et al. were the first to report the use of chitosan as a gene delivery system in 
1995 [20; 75; 81]. Since then, numerous authors have reported studies on chitosan as a 
non-viral vector for DNA [2; 7; 20; 37; 42; 43; 72; 74; 75; 127]. The reasons underlying 
the popularity of chitosan as a gene delivery system are attributable to its favourable 
characteristics such as biocompatibility, biodegradability, low immunogenicity, and 
reduced cytotoxicity compared to other cationic polymers. In addition, chitosan is 
relatively cheap and readily available. [7] Most commonly, chitosan has been 
complexed to DNA by ionic interactions between the negatively charged backbone of 
DNA and the positively charged amine groups of chitosan. This interaction results in a 
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stable complex, in which the chitosan protects the DNA from nuclease degradation. [75] 
Figure 3.3 illustrates the formation of chitosan-DNA nanoparticles through electrostatic 
interaction. Moreover, DNA can also be encapsulated in chitosan nanoparticles via 
traditional nanoparticle preparation methods (section 4.1) or it can be adsorbed on the 
particle surface through non-electrostatic secondary interactions such as hydrogen 
bonding. [75] 
 
 
Figure 3.3. Chitosan-DNA nanoparticles are formed through the electrostatic 
interaction between negatively charged phosphate groups in DNA and positively 
charged amine groups in chitosan. Modified from [75]. 
 
Despite its many favourable characteristics, the low transfection efficiency of 
chitosan still remains a problem [75; 110]. This is due to the relatively low stability and 
buffering capacity of chitosan. Nevertheless, technical progress has allowed chemical 
modification of chitosan whereby its transfection efficiency can be improved without 
harming useful properties such as biocompatibility and biodegradability. [110] 
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4. NANOPARTICLES 
Nanomedicine is concerned with applying nanotechnology to the treatment, diagnosis, 
monitoring, and control of biological systems. Nanotechnology, in turn, relates to 
creating objects, such as nanoparticles, that have at least one dimension of the order of 
100 nanometres or less. One nanometre (nm) can be expressed as the billionth of one 
meter, 1 x 10-9 m. [1, p.22] Nanoparticles are solid colloidal particles that include both 
nanospheres and nanocapsules [79; 113]. Figure 4.1 illustrates the nature of these 
particles. The main difference between nanocapsules and nanospheres is that 
nanocapsules are reservoir particles in which a solid shell encapsulates a liquid phase, 
while nanospheres are particles whose entire mass is solid. Typically, the nanospheres 
are spherical in shape and their size ranges from tenths of nanometres to a few hundred 
nanometres. [113] 
 
Figure 4.1. The nature of nanoparticles including different nanospheres and 
nanocapsules. Modified from [113]. 
  
Nanoparticles possess a vast number of favourable characteristics, which make them 
applicable for drug delivery. Nanoparticles designed for drug or gene delivery are 
capable of entrapping the desired drug or gene in the particle or adsorbing the drug on 
the particle surface. As a result, the drug is protected from instant enzymatic 
degradation in a biological medium.  
The subcellular size of nanoparticles allows higher intracellular uptake than other 
particle systems. In addition, targetability and functionality of nanoparticles can be 
improved by attaching, for example, ligands, polysaccharides or functional groups to the 
particle. [79; 113] Table 4.1 below summarises common materials used in 
nanoparticulate carrier systems. As can be seen from the table, chitosan is one of the 
natural polymers used in drug delivery, in addition to alginate, gelatin and albumin.   
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Table 4.1. Common materials for nanoparticles in drug delivery. [113] 
 
 
Nanoparticle properties may vary depending on the preparation process, particle 
size, zeta potential, pH, or morphology. Therefore, it is important to control these 
parameters to attain desired properties. [79] In addition to chitosan, other common 
polycations for the preparation of polyplexes include poly(ethylenimine) (PEI), 
poly(lysine) (PLL) and poly(ornithine). The resulting internal nanoparticle structure 
prepared by polyelectrolyte complexation can be described as a gel like internal 
structure where the complexed polyelectrolyte chains are swollen by water molecules. 
[113] 
4.1. Preparation of chitosan-DNA nanoparticles 
Various methods, such as complex coacervation, ionic (or ionotropic) gelation, 
chemical cross-linking, as well as solvent evaporation have been used to prepare 
chitosan micro- and nanoparticles [2; 75; 76; 89; 104; 113]. Preparation methods for 
chitosan nanoparticles are summarised in Figure 4.2. 
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Figure 4.2. Fabrication techniques for chitosan particles. [104] 
 
Micro- or nanoparticle preparation methods can also be used to prepare polymeric 
drug or gene delivery devices. Vauthier and Bouchemal have recently reviewed 
preparation techniques for polymeric drug loaded nanoparticles. Also strategies for 
attaining controlled release in vivo are explained in this review. In addition, further 
processing techniques such as sterilisation, lyophilisation and purification are discussed. 
[113] Many nanoparticle preparation techniques include two steps: preparation of an 
emulsified system and formation of nanoparticles. Particle formation is often due to 
precipitation or gelation of the polymer. It is also possible that the particles form already 
in the emulsified system or by another method requiring only one preparation step. For 
example, the self assembly of macromolecules to form polyelectrolyte complexes from 
polymer solutions can be regarded as a one step process. [113] 
In the case of active agent loaded chitosan nanoparticles, the most common 
preparation methods include complex coacervation, emulsion droplet coalescence, ionic 
gelation, and a reverse micellar method [2]. Table 4.2 summarises the preparation 
techniques for chitosan nanoparticles involving specific drugs or components. 
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Table 4.2. Preparation methods of nanoparticles for delivery of different drugs and 
components. Modified from [2]. 
System type Preparation method Drug / component 
 
 
Nanoparticles 
emulsion-droplet coalescence gadopentetic acid 
coacervation/precipitation DNA, doxorubicin 
ionic gelation 
insulin, ricin, bovine serum 
albumin, cyclosporin A 
reverse micellar method doxorubicin 
 
Ultimately, the selected preparation method depends on desired qualities such a 
specific particle size, chemical stability of the active agent, degradation kinetics, as well 
as the stability and residual toxicity of the final product. As can be seen from Table 4.2, 
complex coacervation is used to prepare chitosan-DNA nanoparticles. Recently, an 
osmosis-based preparation technique for chitosan-DNA nanoparticles has also been 
introduced and patented. [2; 76] Because complex coacervation is the method of choice 
for this thesis, only this technique will be elaborated in the following discussion. 
4.1.1. Complex coacervation  
In complex coacervation, an aqueous polymeric solution is separated into two 
immiscible liquid phases: a dense, polymer-rich coacervate phase and a dilute 
equilibrium phase [25]. The basic principle of complex coacervation in chitosan 
nanoparticle preparation is that chitosan is insoluble in alkaline medium, but precipitates 
when it comes into contact with alkaline solution such as NaOH, NaOH-methanol or 
ethanediamine. As a result, particles are formed by blowing chitosan solution into alkali 
solution using a compressed air nozzle. This results in the formation of coacervate 
droplets. The coacervation process is illustrated in Figure 4.3. The size of the droplets 
can be controlled by using specific air pressure or spray nozzle diameters. Finally 
droplets are filtered and purified. A cross-linking agent can be used to harden the 
particles and to facilitate controlled drug release. [2] 
 
 
Figure 4.3. Coacervation using an air nozzle. [2] 
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Coacervation can also be accomplished by adding sodium sulphate or citrate 
dropwise to an aqueous acidic chitosan solution under stirring and ultrasonication for 30 
minutes [2]. The function of sodium sulphate (Na2SO4) is to act as a coacervate agent 
that facilitates the phase separation process of the chitosan solution. However, addition 
of a non-ionic surfactant will stimulate particle formation with the sulphate itself. [53] 
Before addition of sodium sulphate, acetic acid is usually added to dissolve chitosan 
into an aqueous solution. Also sodium acetate solution is added to act as a buffer. In the 
case of water-soluble chitosans addition of acetic acid can naturally be omitted. [74]  
Mao et al. have described in detail the application of complex coacervation for the 
preparation of chitosan-DNA nanoparticles. This method includes heating a chitosan 
solution (0.02% w/v in 5 mM CH3COONa buffer, pH 5.5) and a DNA solution (100 
µg/ml in 5~50 mM Na2SO4 solution) to 50-55°C separately. An equal amount, typically 
500 µl of each solution is mixed and vortexed quickly for about 30 s to yield uniform 
chitosan-DNA nanoparticles. [74] The formation of the particles is based on 
electrostatic interactions between the positively charged chitosan and the negatively 
charged DNA backbone [75].  
4.2. Properties of chitosan-DNA nanoparticles  
This section highlights the properties of different chitosan-DNA nanoparticles prepared 
by complex coacervation. Special attention is paid to factors affecting the size and zeta 
potential of the particles. Also biological properties of nanoparticles will be discussed in 
brief.  
4.2.1. Size 
In the literature, chitosan-DNA nanoparticle size generally varies from 50 to 500 nm 
[74; 76; 81]. However, it should be kept in mind that the variation in preparation 
techniques may affect the size. [75] Polyelectrolyte complexation usually results in sizes 
of tenths of nanometres to a few hundred nanometres [113]. Mumper et al. were the first 
to report the use of chitosan as a gene delivery system in 1995. They concluded that the 
particle size ranging from 150-500 nm was dependent on the molecular weight of the 
chitosan (108-540 kDa). Buffer composition or sugar presence did not affect the size. 
[81] Mao et al. have recently made an extensive literature review concerning the 
different factors affecting chitosan-DNA nanoparticle properties. Research suggests that 
a decrease in molecular weight will also lead to a decrease in particle size. [75] For 
example, Huang et al. found that mean particle size decreased from 181 to 155 nm as 
Mw was reduced from 213 to 48 kDa [37]. However, decreasing the molecular weight 
further caused an increase in particle size and chitosans with a Mw of 10 and 17 kDa 
yielded nanoparticles of size 289 and 269 nm, respectively. [37] On the contrary, 
Maclaughlin et al. discovered that particle size decreases while molecular weight is 
decreased, even if low molecular weight chitosans are used [65]. Figure 4.4 illustrates 
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the correlation between molecular weight, degree of deacetylation, particle size and zeta 
potential. 
 
 
Figure 4.4. a) Effect of molecular weight on particle size and b) effect of molecular 
weight and degree of deacetylation on the size and zeta potential of chitosan-DNA 
nanoparticles. On the x-axis, M and D signify the molecular weight and degree of 
deacetylation, respectively. Modified from [65] and [37]. 
 
In addition to the molecular weight, also chitosan:pDNA charge ratio appears to be 
an important parameter affecting the nanoparticle size [7]. Chitosan:pDNA ratio is 
commonly expressed as the ratio between polymer nitrogen (N) per DNA phosphate (P) 
or N/P. [7; 20] It has been reported that at an N/P ratio of 2 and a zeta potential of 0 mV 
particles will aggregate [20]. Mao et al. also found that the particle size was dependent 
on the N/P ratio and reported particle sizes of 150-250 nm with N/P ratios of 3-8 in a 
complex coacervation process, where a chitosan concentration of 100 µg/ml was used. 
An N/P ratio of 1 yielded large aggregates. Nevertheless, an N/P ratio below 0.75 or 
above 2 produced submicron range particles. The Mw and DD of the chitosan used in 
this study was 390 kDa and 83.5%, respectively. The size of the plasmid, or the sodium 
sulphate concentration had no effect on the particle size. [74] Moreover, Mansouri et al. 
have found that the size of chitosan-DNA nanoparticles prepared by complex 
coacervation is indirectly proportional to the charge ratio, while the zeta potential is 
directly proportional to the charge ratio [71]. As a whole, it could be stated that 
preparation method, molecular weight, and charge ratio are important factors affecting 
the size of chitosan-DNA nanoparticles. However, the exact methods of action of these 
factors remain unclear, and there is a lot of controversy in literature. [20; 37; 65; 71; 74] 
Currently there is also a lack of research addressing the effect of the degree of 
deacetylation on particle size. 
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4.2.2. Zeta potential 
Zeta potential determines whether particles in a liquid are likely to flocculate, and it can 
be used as one factor, in addition to size, pH, and conductivity, to assess the stability of 
particles. Zeta potential is an important parameter in a variety of fields such as 
medicine, pharmaceuticals, water treatment, and brewing. [69] In the case of chitosan 
nanoparticles, the zeta potential can be used to evaluate suspension stability and 
adhesion of particles to biological systems [55]. 
The zeta potential results from the electric charges related to particles in a liquid. A 
positively charged sample will attract negative ions from the surrounding liquid. Ions 
close to the sample surface will bind to it more strongly than ions that are further away. 
This first layer of tightly bound ions on the particle surface forms the Stern layer, while 
the more distant ions form a diffuse layer that is composed of loosely attached 
positively and negatively charged ions surrounding the particle. There is a notional 
boundary within the diffuse layer that separates ions that will move along with the 
particle as it moves in the liquid from those around the boundary that will stay where 
they are. This boundary is referred to as the slipping plane or shear plane. The charge at 
the slipping plane is extremely sensitive to the concentration and types of ions in the 
solution. The zeta potential is, in fact, the electrical potential that exists at the slipping 
plane. [103] Figure 4.5 is a schematic illustration of the zeta potential of a particle. As 
can be seen, the potential decreases as the distance from the particle surface increases.  
  
 
Figure 4.5. Relation between particle surface charge and zeta potential. [67, p.1602] 
 
Particles with a high zeta potential of the same charge will repel each other. In 
general, a potential less than -30 mV and more than +30 mV is considered high. This is 
also the dividing line between stable and unstable suspensions. That is, particles with a 
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zeta potential of less than -30 mV or more than +30 mV are considered stable, whereas 
particles possessing a zeta potential from -30 mV to +30 mV are considered unstable. 
For the latter there is no force preventing molecules from coming together and 
flocculating. [67, p.1602] 
Like chitosan, chitosan nanoparticles also possess a positive surface charge. This is 
explained by residual protonated amino groups of chitosan that do not take part in 
neutralisation with negatively charged DNA. It has been speculated that a higher degree 
of deacetylation would lead to higher zeta potentials as more protonated amino groups 
are available. Also pH has a crucial effect on zeta potential and, in general, zeta 
potential is higher when pH is less than 6 and chitosan is in its protonated form. 
Moreover, also the type of chitosan used may affect the zeta potential. Although N-acyl 
chitosan particles initially have a lower zeta potential than unmodified chitosan, they 
also undergo less reduction of zeta potential when increasing the pH closer to 
physiological conditions.  [55] 
 In the literature, the zeta potential of chitosan-DNA nanoparticles varies between 0 
and 40 mV at a pH of 5.5. The majority of the studies present a zeta potential of 
approximately 20 mV. [37; 55; 74; 80]. Therefore, the majority of zeta potentials 
presented in the literature suggest that particles actually are theoretically unstable. 
Nevertheless, the dividing line of stability at -30 or +30 mV is not always very clear 
[67, p.1602]. Particles possessing a zeta potential of about 20-25 mV may therefore 
sometimes be considered relatively stable [55]. It should be noted that some studies do 
not present which calculation parameters were used while measuring the zeta potential. 
There is also controversy among the parameters that are explained. For example, in the 
study by Moreira et al., a Smoluchowski approximation was used in zeta potential 
calculation, whereas Klausner et al. used a Huckel approximation. [48; 80] This gives 
rise to error, as using a Smoluchowski approximation instead of a Huckel 
approximation yields smaller values for the zeta potential (see Section 5.2.1). However, 
articles usually agree on a measurement temperature of 25°C and a measurement angle 
of 90° or 173° [48; 54; 62; 74]. 
Huang et al. have studied the effect of Mw and DD on the on the transfection 
efficiencies of chitosan vectors. In their study, the correlation between the zeta 
potential, cellular uptake, and transfection efficiency of chitosan-DNA nanoparticles 
was demonstrated. It appears that electrostatic interactions with the cell membrane 
mediate cellular uptake and improve transfection efficiency. The highest zeta potential 
(23 mV) was achieved with a chitosan possessing a DD of 88% and an Mw of 213 kDa. 
This result is illustrated in Figure 4.3b. From the figure it could also be concluded that 
the zeta potential decreases when Mw decreases at a constant DD of 88%. [37] 
Klausner et al. have recently examined chitosan-DNA nanoparticles based on 
NOVAFECT ultrapure chitosan oligomers. It was found that oligomeric chitosan-DNA 
nanoparticles possessed a strong positive surface charge and had a zeta potential of 
44.1 ± 3.5 mV. The size of the particles was small, ≤ 98.2±4.4 nm. They also 
demonstrated good transfection efficiency in vitro. It should be noted, however, that the 
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Huckel approximation yielding higher zeta potential was used in this study. More 
consistency and justification for the use of certain parameters is evidently needed in 
scientific research to make studies more comparable.  [48] Table 4.3 summarises some 
results of chitosan-DNA nanoparticles prepared by complex coacervation. 
 
Table 4.3. Size and zeta potential of chitosan-DNA nanoparticles.  
Chitosan 
Mw 
(kDa) 
Chitosan 
DD 
(%) 
N/P 
Size 
(nm) 
Zeta potential 
(mV) 
pH Reference 
- 87 > 3 260 16 5.5 [80] 
390 83.5 3-6 100-250 12-18 <6 [74] 
60 90 10 167.4 8.6 5.5 [24] 
- - 10 498.6 0.8 7.4 [24] 
150 - 1 
> 1 
7 
>300 
-> 120 
~0 
- 
15 
- [71] 
varies - - ≤ 98 44.1* - [48] 
- - - 148-179.5 12.10-14.6 - [120] 
150 
400 
600 
- - < 100 - 5.5 [15] 
9 
12 
65 
114 
170 
173 
95 
77 
78 
84 
84 
54 
50 
50 
50 
50 
50 
50 
3500 
500 
200 
200 
200 
200 
10-20 
(increased 
slightly with 
higher Mw, 
except 173-54, 
due to low DD) 
5.5 [62]** 
chitosan 
lactate 
20 
45 
200 
460 
87  
 
2,4,8,12,24 
2,4,8,12,24 
2,4,8,12,24 
2,4,8,12,24 
 
 
246.7 ± 6.6 
300.0 ± 3.7 
481.1 ± 12.9 
538.9 ± 15.0 
 
 
28.2 ± 0.30 
30.3 ± 1.10 
35.7 ± 0.80 
35.4 ± 0.10 
- [115] 
*Huckel approximation was used 
** In this study, chitosan-siRNA nanoparticles were prepared  
- Information not available 
 
As can be seen from the table above, the pH has an important role in the 
determination of size and zeta potential. Increasing the pH from 5.5 to the physiological 
pH 7.4 may result in drastic increases in size and reduction of particle stability (see 
[24]). It also appears that the size and zeta potential of chitosan lactate increases with 
increasing Mw with a constant N/P ratio of 12. Another important observation from the 
table is that data concerning specific studies is relatively poor, which makes it difficult 
to compare results.  
Although not much extensive literature exists on the effect of different material 
properties on particle parameters, some studies concerning this have been reported in 
4. Nanoparticles  35 
 
[116]. Weecharangsan et al. prepared chitosan derivatives (chitosan hydrochloride, 
chitosan acetate, chitosan lactate, chitosan aspartate and chitosan glutamate) with 
different molecular weights and N/P ratios and evaluated the effect of these parameters 
on chitosan-pDNA nanoparticle size and zeta potential. The DD of the chitosan was 
87% and pH of the solution was 6.5. It was found that complete complexes formed in all 
chitosans at N/P ratios above 2 in all chitosans of Mw 45 kDa. Particle size increased 
with increasing charge ratio from 1 to 2 and then decreased to constant in the range of 
101-299 nm when N/P was above 2. At N/P 2, the zeta potential was approximately 
neutral but above 2 the zeta potential ranged from 15 to 28 mV. Weecharangsan et al. 
also found that higher Mw chitosans yielded higher particle size and zeta potential than 
LMWCs. Among the chitosan derivatives, the size ranks were the following at N/P 2 
where size was greatest: chitosan glutamate (856 nm) < chitosan aspartate (1276 nm) < 
chitosan acetate (1390 nm) < chitosan lactate 2553) < chitosan hydrochloride (3446 
nm). [116]  
4.2.3. Long-term stability of nanoparticle size and zeta potential  
The stability of physicochemical particle properties, such as size, has been extensively 
studied in vitro. Degradation rate and drug release rate affect the particle size in vivo 
and hence these factors also have an important role in the biocompatibility and toxicity 
of the nanoparticles. Also transfection efficiencies have been explored vastly. [6; 8; 37; 
101] However, there is a lack of information about the long-term stability of chitosan 
based polyplexes ex vivo [101]. Nevertheless, it is equally important to consider stability 
in these conditions as preparation processes may last a long time, particles may not be 
directly used in vivo and in the long term, off-the-shelf nanoparticles may be desired.  
Romøren et al. assessed the long-term transfection efficiencies and the stability of 
chitosan-based polyplexes at different temperatures in an acetate buffer at pH 5.5. It was 
found that storage at 4°C for one year did not result in any major changes in particle 
properties. During storage at 25°C there were minor changes in the physicochemical 
characteristics and the transfection efficiency was reduced. At storage of 45°C, major 
differences occurred in particle properties after a short time. More specifically, particle 
size remained stable over the period of 1 year during storage at 4°C independent of the 
type of chitosan used. However, particle size was affected by storage at 25°C and this 
change was chitosan-type dependent. For instance, chitosan particles with lowest Mn 
(6.6 kDa, DD 83%) increased by 40% in size from an initial size of 148±26 nm, while 
HMWCs increased by 3-14%  At storage of 45°C, a massive increase in particle size 
was observed independent of the chitosan used. [101] 
The zeta potential of the particles stored at 4ºC and 25°C over a period of one year 
decreased by approximately 5 mV, as can be seen from Table 4.4. The particles stored 
at 45°C, however, experienced dramatic changes. [101] 
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Table 4.4. Effect of temperature on chitosan-DNA nanoparticle properties during a 
period of 1 year. Chitosan types SC113 (Mn 6.6 kDa, FA 0.17), SC211 (Mn 90 kDa, FA 
0.32), SC214 (Mn 160 kDa, FA 0.15), SC312 (Mn 160 kDa, FA 0.15). [101] 
 
 
In a study by Bozkir and Saka it was found that particle size and zeta potential of 
chitosan-DNA nanoparticles prepared by complex coacervation does not change 
significantly over a period of 3 months at pH 5.5. However, after lyophilisation with a 
cryoprotective agent, differences in particle sizes were observed.[8] Vauthier and 
Bouchemal have proposed the storage of nanoparticles as solids, as the storage as 
suspensions may result in premature polymer degradation, microbiological 
contamination, loss of drug activity, or physicochemical instability due to particle 
sedimentation or aggregation. The transformation from a liquid system to solids can be 
achieved through freeze-drying or spray-drying processes. However, the applicability of 
these processes to polyelectrolyte complexes is not addressed. [113] 
4.2.4. DNA binding 
One important aspect in the preparation of chitosan-DNA nanoparticles is the binding 
capacity of DNA. Studies have shown that DNA binding is dependent on the degree of 
deacetylation and molecular weight. For example, high molecular weight chitosans bind 
more DNA than medium or low molecular weight chitosans.  If the molecular weight 
remains constant, a higher degree of deacetylation will lead to better binding than lower 
deacetylation. [36; 45] This is most likely due to the fact that a higher DD will result in 
increased positive charge, which enables a higher DNA binding [75]. Huang et al. have 
found that at N/P ratio of 6, more than 90% of the DNA is condensated regardless of the 
DD or Mw. [37] For low molecular weight chitosans of a similar DD, the charge ratio 
must be increased to completely bind the DNA [45].  
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4.2.5. Morphology of chitosan-pDNA nanoparticles 
The morphology of chitosan-DNA nanoparticles has been assessed by using scanning 
electron microscopy (SEM), transmission electron microscopy (TEM) and atomic force 
microscopy (AFM). [15; 45; 47; 74; 77] TEM allows the visualization of DNA inside 
chitosan complexes, while AFM gives a better idea of the size and morphology of the 
particles [15]. Because of the high resolution and ability to yield 3-dimensional images, 
SEM has also been used to evaluate the size and surface morphology of chitosan-DNA 
nanoparticles. However, images differ somewhat depending on the type of SEM and the 
preparation method of the nanoparticles. Figure 4.6 illustrates some SEM images. A 
more detailed description of the function of SEM is presented in Section 5.4. 
 
 
Figure 4.6. a) Chitosan-pDNA (pC1-PDGF) nanoparticles prepared by complex 
coacervation and characterized by SEM. Nanoparticles were about 30-40 nm in 
diameter and of spherical shape. Modified from [59]. b) Chitosan-pDNA nanoparticles 
prepared by complex coacervation. Modified from [74]. c) Chitosan-pDNA 
nanoparticles prepared by an osmosis-based method. Average size 45 (10) nm. 
Modified from [76]. 
 
As can be seen from Figure 4.6, particles are generally of spherical shape. Corsi et 
al. prepared chitosan-DNA nanoparticles by complex coacervation and then 
characterized the particles with TEM and AFM. Their results also indicate that particles 
are of spherical shape and have a diameter of less than 100 nm. Particle size is essential, 
as it has been shown that polycation-DNA complexes mainly enter cells via endo- or 
pinocytosis. For this, it is crucial that the diameter is less than 100 nm. [15] Also Kim et 
al. have found that chitosan-DNA nanoparticles are of spherical shape and have 
compacted structure. The size of the particles depended on the charge ratio of 
galactosylated chitosan to DNA, and it was observed that the size decreased while the 
ratio increased.[47] In a study by Kiang et al. particles were of spherical shape, and the 
size and morphology was not significantly affected by different DDs and charge ratios. 
[45]   
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4.2.6. Biological properties 
Biological properties of chitosan-DNA nanoparticles are usually described in terms of 
transfection efficiency and cytotoxicity in vitro or in vivo. Nanoparticles intended for 
this use are often slightly modified by, for instance, altering pH or adding appropriate 
ligands to enhance cell specific targeting. [2; 15; 20; 37; 71; 74; 107] Mao et al. found 
that transfection of chitosan-DNA nanoparticles is cell-type dependent. In this study 
LipofectAMINETM was used as a control and it was found that transferrin conjugated 
chitosans yielded a 4-fold increase in transfection efficiency in HEK293 and HeLa cells, 
while KNOB protein conjugated particles were able to improve the gene expression 
level in HeLa cells 130-fold. On the other hand, the initial clearance of PEG conjugated 
chitosan nanoparticles in mice was slower than that of unmodified chitosans, despite the 
fact that they did not aggregate upon lyophilisation [74]. Also Corsi et al. used 
LipofectAMINETM as a control to study transfection efficiencies of unmodified 
chitosan-DNA nanoparticles on human osteosarcoma cells (MG63), mesenchymal stem 
cells (MSC) and human embryonic kidney cells (HEK293). It was observed that while 
the transfection efficiency of HEK293 was superior to that of MSC and MG63, it did 
not surpass that of LipofectAMINETM. Cell viability studies by Corsi et al. also 
confirmed the non-toxicity of chitosan. [15; 74] The studies conducted by Mao et al. 
and Corsi et al. demonstrate that surface modification may, indeed, have a crucial role 
impacting the transfection efficiency of chitosan-DNA nanoparticles.  
As mentioned earlier, the most important factors affecting transfection efficiency are 
the size and zeta potential. These were discussed in more detail in the previous sections. 
However, it should be stressed out that generally small size, high surface charge, and 
complex stability facilitate endocytosis and protect the complex in endosomal-
lysosomal conditions before cargo release resulting in higher transfection efficiency. 
[62]  
In addition to transfection efficiency and cytotoxicity, also other biological factors 
such as gene expression and biocompatibility have to be considered in the 
administration of chitosan-DNA nanoparticles. Dai et al. compared the gene expression 
of PEI-DNA and chitosan-DNA nanoparticles in vivo in rat liver, and it was 
demonstrated that chitosan-DNA nanoparticles achieved a 17-fold higher luciferase 
expression than PEI-DNA nanoparticles. [16] Furthermore, Liu et al. studied the 
cytotoxicity and gene expression of chitosan-siRNA nanoparticles on the human lung 
cancer cell line (H1299) that expresses enhanced green fluorescent protein (EGFP). The 
results obtained in the study indicate that chitosan-siRNA nanoparticles prepared from 
higher Mw and DD chitosan show higher gene silencing efficiencies (45-65%) than low 
Mw and low DD chitosan-siRNA nanoparticles. However, the positive control 
(transfection reagent TransIT-TKO), showed an EGFP knockdown of 85%. The 
cytotoxicity test demonstrated that chitosan formulations showed a reduction of 20-40% 
in cell viability compared to the control. The study also suggests that higher N/P ratios 
increase EGFP knockdown. [62]  
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Although plenty of research has been made on transfection efficiency, cell uptake 
and cytotoxicity of chitosan-DNA nanoparticles, information concerning gene 
expression is still incomplete. More knowledge is needed about the degree and impact 
of the desired gene expression in vivo.  
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5. CHARACTERISATION OF CHITOSAN-pDNA 
NANOPARTICLES 
There are a number of characterisation techniques for chitosan-DNA nanoparticles. In 
the literature, dynamic light scattering and laser Doppler velocimetry have been 
extensively used to evaluate particle size and zeta potential, respectively [48; 54; 74]. 
Incorporation of pDNA to the chitosan nanoparticles has been characterised by 
electrophoresis mobility testing in agarose gel containing [43; 48; 74]. The morphology 
of chitosan-DNA nanoparticles has been examined, among other techniques, using 
scanning electron microscopy (SEM) [15; 74; 77].  
5.1. Determining particle size – DLS and FEG-SEM 
There are a number of characterisation techniques for measuring, for instance, the 
size of micro- and nanoparticles. Figure 5.1 specifies the appropriate characterisation 
techniques for different particle size ranges.  
 
 
Figure 5.1. Characterisation techniques for nanoparticles. [70] 
 
As can be seen from the figure, only a few techniques are suitable for the accurate 
characterisation of particles less than 10 nm in size. These include dynamic light 
scattering (DLS), electron microscopy and atomic force microscopy (AFM). DLS is the 
only method which allows particle size measurement in a fast, routine manner without 
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the need of a trained technician. However, electron microscopy and AFM provide more 
information about particle morphology and shape. [70] 
5.1.1. Dynamic light scattering 
Dynamic light scattering (DLS), also known as photon correlation spectroscopy (PCS) 
or quasi-elastic light scattering (QELS), is a technique for measuring the size of small 
particles and molecules in the submicron range. DLS is based on measuring the 
Brownian motion of particles and relating this to their size. The measurement is 
achieved by laser illumination of the samples and by analysing the intensity fluctuations 
of scattered light. In general, particles will scatter light at a certain angle when they are 
illuminated. This scattered light can be observed by placing a detector close to the 
particles, as in Figure 5.2. Light of the same phase will act constructively and form 
bright patches on the screen, while mutually destructive phase additions will appear 
dark. [67, p.1401-1402] 
 
 
 
Figure 5.2. Scattered light passed on to a detector. [67, p.1402] 
 
After the detector has collected a sufficient amount of data, a correlator is used to 
measure the degree of similarity between two intensity signals over a short period of 
time, usually in the order of nano- or microseconds. If the signal intensity at a time (t) is 
compared to itself then there is perfect correlation as the signals are identical. Perfect 
correlation is reported as 1 and no correlation is reported as 0. [67, p.1403] 
In Brownian motion particles move due to the random collision with the molecules 
of the liquid that surrounds them. Small particles move faster than large particles. The 
Brownian motion of particles is related to their size via the Stokes-Einstein equation: 
ܦ ൌ ݇ܶ6ߨߟܴு 
(4) 
where D is the diffusion coefficient, k is the Boltzmann constant, T is absolute tempera-
ture, η is solvent viscosity and RH is the hydrodynamic radius. According to the 
equation, the diffusion coefficient is related to the size of the diffusing object. If the 
other parameters are known, the hydrodynamic radius and the diameter of the particle 
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can be calculated. The hydrodynamic radius is the effective size of the molecule. [67, 
p.1307] 
5.1.2. DLS equipment and operation 
DLS equipment generally comprises six distinctive parts. First, a laser acts as a light 
source to illuminate the particle samples within a cell. Most of the light passes through 
the sample, but some is scattered from the particles. A detector is used to measure the 
intensity of the scattered light. The detector can only measure the intensity successfully 
in a certain intensity range. Therefore, an attenuator is used to reduce the intensity of the 
laser, and hence the intensity of scattered light, if too much light is detected. In contrast, 
the amount of scattered light must be increased for particles that do not scatter very 
much light. These include very small particles or samples of low concentration. In this 
case, the attenuator should allow more laser light through to the sample. After the 
scattered light has been processed by the detector, the scattering intensity signal is 
passed on to a digital signal processor – a correlator. The function of the correlator is to 
compare the scattering intensity at successive time intervals in order to derive the rate at 
which the intensity is varying. Finally, the correlator information is sent to a computer 
where a specific software analyses the retrieved data and determines the particle size. 
[67, p.1406-1407] A schematic presentation of the DLS equipment and process can be 
seen in Figure 5.3. The same measurement equipment can generally be used to 
determine both particle size and zeta potential. However, the cell type and software 
parameters for each are different. 
 
 
Figure 5.3. DLS equipment. 1) laser, 2) cell, 3) detector, 4) "attenuator", 5) correlator , 
6) computer. Modified from [67, p.1406].  
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In some DLS equipment, such as Malvern Instruments Zetasizer Nano ZS, the 
scattering information is measured at an angle of 173°. The method is known as 
backscatter detection and it is based on a technology called NIBS (Non-Invasive-Back-
Scatter). Advantages of this method include reduction in multiple scattering, elimination 
of large particle contaminants such as dust, and measurement of higher sample 
concentrations. [67, p.1407] 
5.1.3. Field emission gun electron microscope 
The scanning electron microscope (SEM) is, in addition to the transmission electron 
microscope (TEM), one of the two main types of electron microscopes. As the names 
indicate, TEM is based on transmitting an electron beam through a thin sample in order 
to obtain an image, while SEM relies on sweeping an electron beam across a specimen, 
and collecting the secondary or back-scattered electrons by an anode connected to a 
cathode-ray-tube. In contrast to TEM, SEM provides a more 3D-like image and is also 
suitable for the observation of thicker samples. Nevertheless, in both TEM and SEM, 
the function of electron microscopes is based on producing a magnified image of a 
sample by illuminating a specimen with a beam of electrons. The narrow electron beam 
is achieved by the objective and the eyepiece lenses that act as magnetic fields bringing 
the electrons to a focus. [26, p.838-839; 125, p.1502-1503] In sample scanning, an 
electron beam is typically emitted from a thermionic electron gun fitted with a tungsten 
filament cathode. The high melting point and low vapour pressure account for the use of 
tungsten in SEM. Also other types of electron emitters are used. For instance, in field 
emission SEM, a field emission gun (FEG) is used. The field emission gun may be a 
cold-cathode type fitted with tungsten single crystal emitters, or it can be fitted with 
zirconium oxide. Compared to conventional thermionic emitters, the field emission gun 
produces an electron beam that is smaller in diameter and more coherent. In addition, 
the current density or brightness is up to three orders of magnitude. As a result, the 
resolution, reliability and signal-to-noise ratio is significantly better in FEG-SEM than 
in conventional SEM emitters.  
The emitted electron beam typically has an energy ranging between 0,5 keV and 40 
keV. After electron emission, the initial beam is focused by condenser lenses to about 
0.4 nm to 5 nm in diameter in the microscope column. The beam then passes scanning 
coils, which deflect the beam over a rectangular are over the sample surface. The energy 
exchange between the electron beam and sample surface results in scattered and 
secondary electrons, as well as electromagnetic radiation, which are detected by specific 
detectors connected to the microscope. The resulting image is obtained by using 
detectors that are sensitive to the particular emission method in question. The detector 
signal then controls the brightness and contrast of the cathode ray tube (CRT) that acts 
as the image screen. [26, p.838-839; 125, p.1502-1503] Nowadays, the SEM is usually 
connected to a computer, which allows observation on a computer screen and saving the 
image on a computer hard disc. [34, p.134] A schematic illustration of the scanning 
electron microscope is presented in Figure 5.4.  
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Figure 5.4. Scanning electron microscope. Scanning coils move an electron beam 
across the sample surface. Secondary electrons are collected and modulate the intensity 
in the CRT to produce a picture. Modified from [26, p.838]. 
 
In secondary electron emission, the image is formed due to differences in the surface 
topography, which results in differences in contrast. When the secondary electron hits 
the scintillator material, a light signal is formed and it is optically guided to the light 
multiplier tube.  Signals are collected, amplified and passed to a cathode ray tube, where 
the image is formed. Back-scattered electrons are a result of the atomic number of the 
atoms in the sample surface. In general, heavier elements will cause lighter areas in the 
SEM image than lighter elements. When back-scattered electrons migrate to the 
semiconductor detector, they form a current that is conducted to amplifiers and the 
image is formed on a cathode ray tube. [34, p.154] 
The resolution of the SEM depends on the brightness and the electron beam size on 
the sample surface [34, p.154]. Theoretically, the resolution can be as small as the 
wavelength of an accelerated electron. For example, an electron accelerated by a voltage 
on the order of 105 V has a wavelength on the order of 0.004 nm. [26, p.838] In general, 
the higher the voltage the better the resolution, as demonstrated in Equations 5 and 6: 
ߣ ൌ ݄݉ݒ (5) 
ݒ ൌ ඨ2ܷ݁݉  (6) 
where λ is the wavelength of an electron, h is Planck’s constant, m is the mass of an 
electron, v is the velocity of an electron, e is the charge of an electron and U is the 
acceleration voltage. In practice, aberrations in the magnetic lenses limit the maximum 
resolution of the scanning electron microscope to 1-10 nm. The use of high voltages is 
limited with biological samples, as the generated heat may cause damage to the 
specimens. [26, p.836-839; 34, p.154-155] Moreover, biological material is often coated 
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by carbon or with an adequate metal in order to increase conductivity of the specimen 
and thus improve image quality. [34, p.154] 
5.2. Determining zeta potential- Laser Doppler 
Velocimetry 
Zeta potential is calculated by Laser Doppler Velocimetry (LDV). When an electric 
field is applied to an electrolyte, charged particles move to the electrode of opposite 
charge. However, the viscosity of the solution opposes this movement. When a balance 
is achieved between the opposing forces, the particles move with constant velocity, 
referred to as electrophoretic mobility, and Henry’s equation (Equation 7) can be 
applied to calculate the zeta potential: 
ܷா ൌ 2ߝݖ݂ሺ݇ܽሻ3ߟ  (7) 
where UE is the electrophoretic mobility, z is the zeta potential, ε is the dielectric 
constant, η is viscosity and f(ka) is the Henry function. There are two values commonly 
used to approximate the Henry function. In aqueous media f(ka) is normally 1.5. This 
value is also known as the Smoluchowski approximation and it is suitable for particles 
larger than 0.2 microns dispersed in electrolytes containing more that 10-3 molar salt and 
high ionic strengths. For non-aqueous solutions or for small particles in a low dielectric 
media, f(ka) 1 is used and it is referred to as the Huckel approximation. Both the 
Smoluchowski and the Huckel approximation have been used in studies concerning 
chitosan-DNA nanoparticles. [48; 80] 
As can be seen from Henry’s equation, the electrophoretic mobility has to be known 
in order to calculate the zeta potential (z). Laser Doppler Velocimetry is used to 
measure the velocity of tiny particles within a fluid. This includes scattering light at an 
angle of 17° and combining it with a reference beam. Once again a fluctuating intensity 
signal is produced. This signal is proportional to the velocity of the particles and hence 
the electrophoretic mobility can be calculated with the help of a digital signal processor. 
When the electrophoretic mobility is known, the zeta potential can be calculated 
according to Equation 7. [67, p.1604-1605] Considering Equation 7, it could be noted 
that the zeta potential is directly proportional to the viscosity and materials with higher 
viscosities should therefore be expected to have higher zeta potentials. A schematic 
representation of the measurement of electrophoretic mobility is given in Figure 5.5. 
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Figure 5.5. Principles of LDV in measuring the zeta potential. [67, p.1606]  
 
The most important factor affecting the zeta potential is pH. For example, adding 
alkali to a solution with a negative charge will cause the particles to acquire more 
negative charge, whereas adding acid may neutralise or build up a positive charge of the 
solution. [67, p.1602-1603] This effect is visualised in Figure 5.6. 
 
Figure 5.6. A typical plot of zeta potential versus pH. [67, p.1603] 
 
As can be seen from Figure 5.6, the zeta potential versus pH curve will be positive 
at low pH and lower or negative at high pH. The point where the curve passes zero zeta 
potential is called the isoelectric point. At this point the colloidal system is least stable. 
[67, p.1603] In literature, zeta potential is commonly measured at a temperature of 25°C 
and at a scattering angle of 90° or 173°, depending on the measuring device [48; 71; 74; 
80].  
5.3. DNA incorporation - gel electrophoresis 
Electrophoresis can be used in combination with other methods like LDV, as described 
in the previous section. However, it can also be used to determine the size, molecular 
weight, isoelectric point or biological activity of different compounds. Although 
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electrophoresis can be conducted using different media such as gel or paper, in literature 
agarose gel electrophoresis has successfully been applied to assess the incorporation of 
DNA into chitosan nanoparticles. [15; 71; 74] Hence, agarose gel electrophoresis is also 
used in this particular study to evaluate the success of DNA and chitosan nanoparticle 
complexation.  
5.3.1. Physical principles of gel electrophoresis – sample mobility 
Electrophoretic methods are based on the migration of charged ions or molecules 
towards an anode or cathode in an electric field. Positively charged molecules will 
migrate towards the negative cathode, whereas the positive anode attracts negatively 
charged anions. [34, p.162] This process is referred to as electrophoresis, and it is 
illustrated in Figure 5.7 [73, p.48]. The higher the charge of the particle and the applied 
voltage, the faster the compounds will move in the electric field. In addition, smaller 
particles will move through the field medium faster than larger molecules, especially if 
a restrictive medium is applied to act as a molecular sieve. If particles are of the same 
size, they can be differentiated according to their charge. If particles possess the same 
charge, they can be differentiated according to size. [73, p.49 and 56]  
 
 
Figure 5.7. The basic principle of electrophoresis. Positively charged particles migrate 
towards the negatively charged cathode and negatively charged ions migrate towards 
the anode. [73, p.48] 
 
In electrophoresis molecule samples are prepared accordingly and then loaded to 
wells in a non-conductive matrix such as agarose or polyacrylamide gel. The medium, 
often covered by a conductive aqueous buffer, is then connected to a power supply by 
electrodes and an electric field is applied. Typically voltages from 200 to 500 V and 
currents from 100 µA to 400 mA are used. The pH is usually chosen so that most 
analytes will be negatively charged and migrate toward the anode. In the case of 
chitosan-DNA nanoparticles, a voltage of 80-100 V and a current of 400 mA are chosen 
on a 0.8% agarose gel, and the gel is run for about an hour. [45] Figure 5.8 illustrates a 
typical gel electrophoresis setup. 
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Figure 5.8. Gel electrophoresis setup. The gel containing sample wells is placed in a 
buffer container, which is attached to a DC power supply with electrodes. [73, p.58] 
 
An electrophoresis apparatus can be considered as a simple DC circuit composed of 
one voltage source connected to three resistors in series, namely two electrode buffer 
chambers and a medium such as gel. Because most of the resistance is provided by the 
gel slab that is both longer in length and has a smaller cross-section than the electrode 
chambers, it is usually sufficient to consider the gel as the only resistor connected to the 
power supply. The electrical current of the circuit consists of both sample molecules and 
buffer ions of which the latter represent the majority of the current. As a voltage is 
applied to the system, cations migrate towards the cathode and anions as well as 
negatively charged sample molecules move towards the anode. [83]  
As illustrated in Figure 5.8, the matrix material and conductive buffer are connected 
to a power supply. Two principles of electricity can be applied to gel electrophoresis: 
Ohm’s law and the power equation. [34, p.163; 83] Ohm’s law can be expressed as  
V = RI (8) 
where V is the voltage between the cathode and anode, I is the current passing the 
electric field and R is the resistance of the field. It should be noted that although the 
above equation is often referred to as Ohm’s law, the actual content of Ohm’s law 
expresses the direct proportionality of V to I only when R is constant. [125, p.951] The 
power equation, on the other hand, is 
P = VI or P = I2R or ܲ ൌ ௏మோ  (9) 
where P is power. The power equation is a variation of Ohm’s law and it illustrates how 
a small change in current can introduce large changes in the expenditure of power. [125, 
p.970]  
The applied electric field generates the movement of particles and allows separation 
of molecules due to differences in electrophoretic mobility [73, p.49-50]. The 
electrophoretic mobility describes the ratio between the migration velocity and the 
electric field strength and can be expressed with equation 10: 
µ௘௣ ൌ
ݒ௘௣
ܧ ൌ
ݍ
6ߨߟݎ (10)
assuming a constant electric field in which the electric and frictional force are equal. 
Also electroosmotic force (EOF) and Joule heating affect particle separation. However, 
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these will not be elaborated in the scope of this study. For more information about EOF 
and Joule heating, see reference Manz et al. [73, p.49-50]  
5.3.2. Agarose gel electrophoresis 
In gel electrophoresis, the medium through which the sample molecules migrate 
commonly consists of an agarose or polyacrylamide (PA) gel [73, p.56]. The purpose of 
the porous matrix material is to provide greater resistance for larger molecules, reduce 
convection currents and inhibit sample diffusion [83]. In addition, samples can be fixed 
on the solid matrix and be detected in post-electrophoretic analysis. Agarose gel 
electrophoresis can be used to, for example, view, separate, purify, or isolate DNA 
fragments [29]. It can also be used for polymerase chain reactions (PCR) [10, p.154]. 
 Agarose is a natural, linear polysaccharide derived from seaweed and it is 
composed of repeating agarobiose units. Agarobiose consists of alternating units of 1,3-
linked b-D-galactopyranose and 1,4-linked 3,6-anhydro-a-L-galactopyranose. [9, p.91] 
Typically the pore size of agarose gel is bigger than that of polyacrylamide gel. Agarose 
gel is therefore more suitable for the separation of bigger nucleic acid molecules (> 400 
base pairs). Agarose gel electrophoresis has often been used in the characterisation of 
chitosan-DNA nanoparticles. [15; 71; 74] Agarose gel is also faster to prepare and safer 
to handle than PA gel. [73, p.59] 
To prepare agarose gel, agarose powder is mixed with a buffer such as Tris Borate 
EDTA (TBE) or Tris Acetate EDTA (TAE). Commonly, concentrations of 0.7 – 2 % 
are used. Smaller concentrations will show better resolution for bigger DNA fragments 
(5-10 kbp) and higher concentrations will provide better separation of smaller DNA 
fragments (0.2-1 kbp). [84] Typically, a 0.8% agarose gel has been applied for chitosan-
DNA nanoparticles [71; 74]. Usually ethidium bromide or an alternative DNA gel stain 
is added to the gel for visualisation of DNA. [71] Ethidium bromide intercalates 
between the bases of DNA and due to its fluorescent nature it absorbs UV light. [56] 
More detailed information about gel and sample preparation is readily available [85].    
When gel electrophoresis is complete, the gel slab is usually removed from the 
buffer container and further studies are conducted. For example, a UV illuminator can 
be used to visualise sample movement on the gel [105]. Normally DNA marker and 
plasmid DNA should “run” on the gel due to the negatively charged ions in their 
structure. However, if a sample does not have a negative net charge, it will not migrate 
on the gel. This should be the case with chitosan-DNA nanoparticles. [20; 74]  
5.4. Statistical analysis 
The statistical significance of chitosan-pDNA nanoparticle properties has been assessed 
by both non-parametric tests, such as the Mann-Whitney U test, and parametric tests 
like the Student’s t-test. [4; 90]  
The Mann-Whitney U test is used to compare two population means from the same 
population. As the test is non-parametric, it does not make any assumptions of the 
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sample distribution. Instead, the Mann-Whitney U test assumes that samples are 
randomly drawn from the population, samples are mutually independent and the 
measurement scale is ordinal. The Mann-Whitney U test is calculated by Equation 11. 
[106] 
ܷ ൌ ݊ଵ݊ଶ ൅ ݊ଶ ሺ݊ଶ ൅ 1ሻ2 – ෍ ܴ௜
௡మ
௜ୀ ௡భା ଵ
 (11)
where n1 is sample size one, n2 is sample size two and R is the rank of the sample size. 
U is the value of the Mann-Whitney U test. [106] 
Also the Student’s t-test is used to compare the means of two samples. [78, p.118] 
This parametric test assumes a normal distribution of the samples. When samples sizes 
and variances are expected to be equal, Equation 12 is used to calculate the value of t: 
ݐ ൌ തܺଵ െ തܺଶ
ܵ · ට1݊ଵ ൅
1
݊ଶ
 (12)
 
ܵଶ ൌ ሺ݊ଵ െ 1ሻݏଵ
ଶ െ ሺ݊ଶ െ 1ሻݏଶଶ
݊ଵ ൅ ݊ଶ െ 2  (13)
where X1 is the mean of sample one, X2 is the mean of sample two, n is the number of 
participants in each sample, and s1 and s2 are the standard deviations of the samples. S2 
is an estimate of the common variance of the samples and it can be calculated using 
Equation 13. When measuring significance, the degrees of freedom can be calculated as 
(2n – 2). When t has been calculated and the degrees of freedom have been determined, 
the statistical significance can be evaluated by using a t distribution table. A null 
hypothesis assuming that there is no difference in the sample means is usually applied 
when using the t-test. Hence, if the calculated value of t exceeds the value given in the 
table, the null hypothesis is rejected. In this case, the sample means are considered 
significantly different at the chosen level of probability. [21, p.366; 78, p.118-122; 86]  
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6. MATERIALS AND METHODS 
6.1. Materials for chitosan-pDNA nanoparticle preparation 
Chitosans were purchased from Heppe Medical Chitosan (Germany) and FMC 
BioPolymer/Novamatrix (Norway). The chitosans and chitosan salts and derivatives 
used in this study, as well as some of their properties, are presented in Table 6.1. 
 
Table 6.1. Chitosans used for the preparation of chitosan-DNA nanoparticles. 
Chitosans written in bold are water-soluble chitosan salts and derivatives. 
Nr Chitosan 
Sample 
name 
DD 
(%) 
Mw 
(kDa) 
Manufacturer (country) 
1 Chitoceuticals Chitosan 75/5 75/25 76.5 25 
Heppe Medical Chitosan 
(Germany) 
 
2 Chitoceuticals Chitosan 85/5 85/25 84.3 25 
3 Chitoceuticals Chitosan 95/5 95/25 94.5 25 
4 Chitoceuticals Chitosan 75/50 75/150 74.1 150 
5 Chitoceuticals Chitosan 85/50 85/150 83.7 150 
6 Chitoceuticals Chitosan 95/50 95/150 92.8 150 
7 Chitoceuticals Chitosan 75/200 75/300 74.9 300 
8 Chitoceuticals Chitosan 85/200 85/300 87.3 300 
9 Chitoceuticals Chitosan 95/200 95/300 94.3 300 
10 
Chitosan base 
(PROTASAN UP B 80/20) 
80/250 86 250 
FMC BioPolymer/NovaMatrix 
(Norway) 
11 
Chitosan base 
(PROTASAN UP B 90/500) 
90/460 91 460 
FMC BioPolymer/NovaMatrix 
(Norway) 
12 Chitosan acetate 
CH ace 
(85/100) 
83.6 100 
Heppe Medical Chitosan 
(Germany) 
 
13 Chitosan lactate 
CH lac 
(95/400) 
93.4 400 
14 Chitosan hydrochloride 
CH HCl 
(95/40) 
91.7 40 
15 Chitosan oligosaccharide 
CH oligo 
(85/1.5) 
83.1 1,5 
16 Carboxymethylchitosan 
CMCH 
(95/150) 
94.4 150 
17 
Chitosan glutamate 
(PROTASAN UP G 113) 
CH glut 
(86/) 
86 50-200 
FMC BioPolymer/NovaMatrix 
(Norway) 
 
 The specific molecular weight of chitosan glutamate was not specified and hence it 
is omitted from the sample name. According to the manufacturer, the molecular weight 
should be from 50 to 200 kDa. In addition to chitosan, chemical reagents and physical 
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equipment were used in combination with chitosan to form chitosan-pDNA 
nanoparticles. These are presented in Table 6.2. 
 
Table 6.2. Additional materials in chitosan-DNA nanoparticle preparation. 
Reagent (chemical formula) Manufacturer/Supplier (city, country) 
Sodium sulphate (Na2SO4) Merck (Darmstadt, Germany) 
Sodium acetate (CH3COONa) Merck (Darmstadt, Germany) 
Acetic acid (CH3COOH) J.T. Baker (Deventer, Holland) 
Sodium hydroxide (NaOH) J.T. Baker (Deventer, Holland) 
Hydrochloric acid (HCl) Sigma-Aldrich (Helsinki, Finland) 
Plasmid DNA expressing GFP (green fluorescent 
protein) (500 ng/µl)  
University of Tampere (Tampere, Finland) 
Equipment  Manufacturer/Supplier (city, country) 
Magnetic stirrers: 
Schott 
Ikamag® REO 
 
Schott Geräte GmBh (Mainz, Germany) 
Ika® Werke GmBh & Co. (Staufen, Germany) 
pH meter: Mettler Toledo 225 Mettler Toledo (Greifensee, Switzerland) 
0.2 µm syringe filters PALL Life Sciences (Washington, U.S.A.) 
5 ml syringes BD DiscardIt™ II (U.S.A.) 
 
Other essential materials included regular laboratory equipment.  
6.2. Equipment in nanoparticle characterisation and gel 
electrophoresis 
After particle preparation, another set of materials was used to characterise the particles. 
Reagents and devices are presented in Table 6.3.  
 
Table 6.3. Reagents and devices in chitosan-pDNA nanoparticle characterisation. 
Reagent Manufacturer/Supplier (city, country) 
Multipurpose agarose Bioline (London, U.K.) 
10,000x SYBR® Safe DNA gel stain Invitrogen, part of Life Technologies™ (U.S.A.) 
10 x TBE (Tris-borate-EDTA buffer) 
6x DNA Loading Dye #0611 
GeneRuler™ 1kb DNA Ladder 
Fermentas Life Sciences (Canada) 
 
Equipment Material/Supplier (city, country) 
Zetasizer Nano ZS Malvern Instruments (Worcestershire, U.K.) 
UV-transparent disposable cuvettes Sarstedt (Nümbrecht, Germany) 
Sub-cell GT Cell, Mini-sub cell GT Cell Bio-Rad Laboratories (California, U.S.A.) 
Electrophoresis Power Supply – EPS 300 Pharmacia Biotech (Uppsala, Sweden) 
UV illuminator/CCD camera: Molecular imager 
Chemidoc™ XRS System 
Bio-Rad Laboratories (California, U.S.A.) 
Slide-A-Lyzer® 10K Dialysis Cassettes Thermo Scientific (Rockford, U.S.A.) 
Zeiss ULTRAplus FEG-SEM Carl Zeiss SMT AG (Germany) 
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Other essential materials included regular laboratory equipment.  
6.3. Preparation of chitosan-pDNA nanoparticles by 
complex coacervation 
Each nanoparticle batch was prepared in two stages on two consecutive days. The first 
day involved weighing materials and preparing solutions. The second day, solution pH 
was adjusted and plasmid DNA was added to the chitosan solutions in order to form 
chitosan-pDNA nanoparticles. Below is a more detailed description of the nanoparticle 
preparation process.  
6.3.1. Preparation of solutions 
Briefly, a 200 µg/ml chitosan solution was prepared by weighing 8 mg of the desired 
chitosan and mixing it with 20ml of distilled water and 20 ml of 100 mM sodium 
acetate (CH3COONa) solution. However, if the chitosan was non-soluble in water, 114 
µl of acetic acid (CH3COOH) was pipetted in the water solution in order to dissolve the 
chitosan, and the solution was left to mix on a magnetic stirrer for about an hour before 
the addition of sodium acetate solution. The basic principle of the first stage of particle 
preparation is illustrated in Figure 6.1. 
 
Figure 6.1. Preparation of solutions – stage 1 a) Chitosan (CH) is weighed and 
inserted to a glass bottle. Distilled water is added and the solution is placed on a 
magnetic stirrer b) Acetic acid is added, if necessary, and the solution is placed back on 
the magnetic stirrer for ~1h. 100 mM of sodium acetate is added and the solution is left 
to mix at ~270 rpm overnight. 
 
6. Materials and methods  54 
 
In detail, 8 mg of chitosan was weighed and inserted into a 50 ml glass bottle. 20 ml 
of distilled water was added to the bottle using a 10 ml automatic pipette. A magnetic 
rod was placed into the bottle, the glass bottle was closed with a cap, and the mixture 
was placed in a magnetic stirrer (~350 rpm) for about 5-10 minutes. Thereafter, if 
needed, 114 µl of acetic acid was added using a pipette and the solution was left to mix 
on the magnetic stirrer for about an hour. Finally, 20 ml of 100 mM sodium acetate 
solution was added with a 10 ml pipette and the resulting solution was mixed on the 
magnetic stirrer (~270 rpm) overnight at room temperature. If there were more chitosan 
samples to be prepared than one, the steps described above were applied to each sample.  
100 mM CH3COONa solution was prepared whilst the chitosan-acetic acid solution 
was mixing on the magnetic stirrer. First, 574 mg of CH3COONa was weighed in a 100 
ml glass bottle. Thereafter, 70 ml of distilled water was added using a 10 ml pipette. 
Finally, a magnetic rod was placed in the bottle, the bottle was closed with a cap and the 
solution was mixed on a magnetic stirrer for about an hour before it was added to the 
chitosan solution.  
Also sodium sulphate solution (5 mM Na2SO4) was prepared on the first day of 
nanoparticle preparation. For this, 28.4 mg of Na2SO4 was measured in a weighing boat 
and then poured into a 50 ml glass bottle. The weighing was executed simultaneously 
with chitosan weighing. The desired amount of distilled water, in this case 40 ml, was 
added to the glass bottle using a 10 ml pipette. A magnetic rod was placed in the bottle, 
the bottle was closed with a cap, and then placed on a magnetic stirrer for a couple of 
hours. Finally, the solution was removed from the stirrer and left to stay at room 
temperature overnight. Table 6.4 summarises the amount of reagents used for each 
solution. 
 
Table 6.4. Reagents used in solution preparation. 
Reagent 
200 µg/ml chitosan 
solution 
100 mM CH3COONa 
solution 
5 mM Na2SO4 solution 
Chitosan 8 mg - - 
Distilled water 20 ml 70 ml 40 ml 
Acetic acid (114 µl) - - 
100 mM CH3COONa 20 ml - - 
CH3COONa - 574 mg - 
Na2SO4 - - 28.4 mg 
 
In addition to preparing solutions, the desired number of test tubes was cleaned and 
left to dry for the next day.  
6.3.2. Adjusting pH and formation of chitosan-pDNA nanoparticles 
On the second day of chitosan nanoparticle preparation, the 5 mM Na2SO4 solution 
prepared on the previous day was first placed back on the magnetic stirrer. Then, half of 
the chitosan solution was poured into another glass bottle and the pH of the remaining 
solution (~20 ml) was adjusted to approximately 5.5 with 10 M NaOH or with 1 M HCl, 
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depending on the initial pH. Also the pH of the 5 mM Na2SO4 solution was checked, 
but not adjusted. The pH meter was calibrated before use and the electrode of the meter 
was rinsed and dried both before use and between switching samples.  
Next, plasmid DNA (pDNA) was taken from the freezer to melt. The aim was to 
prepare a 1.2 ml sample of chitosan-pDNA nanoparticle solution with a chitosan:pDNA 
weight ratio of 4:1. Simply put, this was achieved by mixing 600 µl of chitosan solution 
with 600 µl of pDNA-Na2SO4 solution. In detail, pH-adjusted chitosan solution was 
filtered to a plastic test tube using a 0.2 µm syringe filter and a 5 ml syringe. The 
function of filtering was to remove insoluble chitosan and impurities from the solutions. 
Also 5 mM Na2SO4 solution was filtered to a separate test tube. Then, 600 µl of the 
filtered chitosan solution was extracted and pipetted to another test tube. The volume of 
extracted filtered 5 mM Na2SO4 solution to another test tube was dependent on the 
volume of plasmid DNA which, in turn, depended on the concentration of the plasmid 
(500 ng/µl). For a CH:pDNA weight ratio of 4:1, 60 µl of pDNA was needed. 
Therefore, to achieve a Na2SO4-pDNA solution of 600 µl, 60 µl of plasmid pDNA was 
pipetted to 540 µl of 5 mM Na2SO4 solution. Table 6.5 summarises the amounts of 
reagents used for preparing a chitosan-pDNA nanoparticles with a weight ratio of 4:1 
from a 200 µg/ml chitosan solution. 
 
Table 6.5. Amounts of reagents used for chitosan-DNA nanoparticles.  
Reagent 200 µg/ml chitosan solution 
Volume of chitosan solution 600 µl 
Mass of chitosan 120 µg 
Volume of (5 mM Na2SO4-pDNA) 600 µl 
Concentration of pDNA 0.5 µg/µl 
Volume of pDNA 60 µl 
Mass of pDNA 30 µg 
Volume of 5 mM Na2SO4 solution 540 µl 
Total sample volume 1.2ml 
 
After pipetting filtered chitosan and (Na2SO4- pDNA) solutions (à 600 µl), test tubes 
were placed in a water bath in a 1000 ml decanter containing a magnetic rod. The 
decanter was covered with aluminium foil to protect samples from light. Finally, the 
bath was heated to 55°C while simultaneously stirring the bath on a magnetic stirrer 
(300 rpm). When the temperature reached 55°C, the decanter was removed from the 
heater and magnetic stirrer.  
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Figure 6.2. Preparation of chitosan-pDNA nanoparticles - stage 2 a) The pH of the 
chitosan (CH) solution was adjusted to 5.5 by 10M NaOH or 1M HCl. b) The chitosan 
and 5mM Na2SO4 solutions were filtered and the appropriate amount of each solution 
was pipetted to a separate test tube. c) The solutions were placed in a water bath on a 
magnetic stirrer and they were heated to 55°C at 300 rpm. Test tubes were removed and 
the Na2SO4-pDNA solution was pipetted to the CH solution. The sample was vortexed 
for 30 s to yield nanoparticles. The yellow sample represents CH solution and the blue 
sample Na2SO4-pDNA solution for illustrative reasons. In reality, the solutions were 
clear.  
 
After the heating, 600 µl of Na2SO4-pDNA solution was pipetted up and down to 
600 µl of the chitosan solution. Finally, chitosan-pDNA nanoparticles were formed by 
vortexing the mixed solution for 30 seconds. The sample was left to stand in room 
temperature for 30-60 minutes before further investigations. Figure 6.2 summarises the 
steps of chitosan-pDNA nanoparticle preparation. 
6.4. Size and zeta potential measurement 
Particle size and zeta potential was determined by dynamic light scattering and laser 
Doppler velocimetry, respectively. Measurements were performed approximately 1−4 
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hours after particle preparation using Zetasizer Nano ZS (Malvern Instruments, United 
Kingdom).  
Samples were quickly vortexed before measurements. For size determination, a   
100 µl sample of the chitosan-pDNA solution was pipetted in a cuvette that was inserted 
in the measuring device. Appropriate parameters, presented in Table 6.6, were set on the 
device software and the measurement was initiated. The procedure described above was 
repeated three times for each chitosan sample and for each 100 µl sample 3 subruns 
were performed. Thus, 9 values were obtained for each sample. After initial size 
measurements, particles were stored still at 4°C. The stability of particle size was 
evaluated on week 1 and week 2 after particle preparation. The same measurements 
settings were used during these experiments. 
 
Table 6.6. Software parameters used in size and zeta potential measurements. 
Parameter 
Specifications 
Size 
Specifications 
Zeta potential 
Measurement 
type 
Size Zeta potential 
Material 
Chitosan 
RI 1.33, absorption 0.00 
Chitosan 
RI 1.33, absorption 0.00 
Dispersant 
Water, temperature 25°C, 
viscosity 0.8872, RI 1.33 
Water, temperature 25°C, 
viscosity 0.8872, RI 1.33 
Temperature 
25°C 
Equilibration time 60 s 
25°C 
Equilibration time 60 s 
Cell/cuvette 
ZEN0117 
disposable low volume cuvette (100 µl) 
DTS1060C 
clear disposable zeta cell 
Measurement 
Angle 173° Backscatter (NIBS default) 
Measurement duration: automatic 
Number of measurements: 3 
Delay between measurements: 0 
Number of measurements: 3 
General - Smoluchowski f(ka) = 1.5 
   
In zeta potential measurements, approximately 750 µl of chitosan sample was 
pipetted into an electrode cuvette. The cuvette was cleaned with ethanol and water 
between switching samples. The zeta potential was measured by inserting the cuvette 
containing the desired sample into the Zetasizer and setting the right parameters on the 
device software. Table 6.6 above presents the parameters used in zeta potential 
determination. Only one measurement with three subruns was performed on each 
sample, resulting in 3 values for the zeta potential.  
6.5. Agarose gel electrophoresis 
Agarose gel electrophoresis was performed on the chitosan-pDNA solutions the day 
after size and zeta potential determinations. A 0.8% agarose gel was prepared by 
weighing the agarose in a decanter, adding 1xTBE and heating the mixture up in a 
microwave oven on full power. The solution was mixed every now and then to ensure 
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mixing of the agarose powder to the TBE solution. When the solution was clear, it was 
removed from the microwave and it was cooled down to approximately 65°C before 
adding SYBR® Safe DNA gel stain. Finally, the mixture was poured on a gel plate and 
the sample well comb was inserted on the gel. The gel was left to stiffen for about an 
hour, while preparing the samples. Table 6.7 presents the amounts of reagents used for a 
big and small gel plate. The size of the gel was dependent on the available equipment. 
 
Table 6.7. Reagents used for agarose gel. 
Reagent 0.8% small gel 0.8% big gel 
Multipurpose agarose 0.48 g 1.2 g 
1 x TBE 60 ml 150 ml 
SYBR® Safe DNA gel stain 6 µl 15 µl 
 
Gel samples were prepared by mixing 20 µl of chitosan-pDNA solution with 4 µl of 
loading dye (6 x DNA Loading Dye, Fermentas Life Sciences). DNA ladder was used 
as a reference and it was prepared by mixing 6 µl of sterilised water, 1.5 µl of loading 
dye and 1.5 µl of DNA ladder (GeneRuler™ 1kb, Fermentas Life Sciences). Plasmid 
DNA was used as the control and the pDNA sample was prepared by pipetting 2 µl of 
plasmid and 0.4 µl of loading dye. Finally, gel samples were vortexed and spinned 
quickly to ensure the uniformity of the solutions.  
When the gel had stiffened, the well comb was removed from the gel and the 
possible tapes surrounding the gel plate were removed. The plate containing the gel was 
then placed to a gel electrophoresis apparatus and 1xTBE was poured into the apparatus 
until the gel was covered. Gel samples were loaded in gel wells in the following order: 
DNA ladder, plasmid, chitosan-pDNA samples. The gel apparatus was connected to a 
power supply and the gel was run at 80 V and 400 mA for approximately an hour. Table 
6.8 demonstrates the amount of reagents used for each gel sample and the amount of the 
gel sample loaded on the gel. 
 
Table 6.8. Preparation of samples for agarose gel electrophoresis. 
Reagent 
DNA ladder 
GeneRuler™ 1kb 
Plasmid 
Chitosan-pDNA 
solution 
Sample 1.5 µl 2 µl 20 µl 
6x DNA loading dye 1.5 µl 0.4 µl 4 µl 
sterilised water 6 µl - - 
amount of sample on gel 9 µl 2.4 µl 20 µl 
 
When the gel electrophoresis was complete, the gel slab was removed from the 
plate, and it was inspected and visualised under UV light using molecular imager 
Chemidoc XRS System and appropriate software (Quantity One) in order to detect 
migration of the samples.  
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6.6. Particle characterisation using FEG-SEM 
Based on obtained results shown in Appendix 1, three samples were chosen for 
morphological studies. These included chitosan 85/25, chitosan HCl and chitosan 
80/250. The last was used as a reference, while the previous were chosen based on the 
promising nanoparticle size. Samples were prepared according to instructions given in 
section 6.3. A small amount of the sample was separated for size measurement 
comparison. Then, samples were dialysed in order to remove salts from interfering with 
the microscope image. First, a small amount of sample was injected to a dialysis 
cassette (Thermo Scientific). Then, a buoy was attached to the cassette and the sample 
was placed on a magnetic stirrer in a sterilised water bath. The dialysis fluid was 
renewed after a few hours and finally the system was left on a magnetic stirrer 
overnight. On the next day, the sample was removed from the cassette using a syringe. 
Size measurements were performed on non-dialysed and dialysed samples. Figure 6.3 
illustrates the dialysis procedure.  
 
Figure 6.3. Dialysis of chitosan-pDNA solution. a) The sample is injected to the 
cassette by inserting the syringe needle through the gasket via one of the corner points 
in the cassette. b) A float buoy is attached to the cassette and dialysis is performed. c) 
The sample is withdrawn by inserting a needle in one of the unused corners of the 
cassette. [109] 
 
The remaining dialysed samples were prepared for FEG-SEM imaging. Basically, a 
small amount of the chitosan-pDNA solution was injected on a TEM grid and the 
sample was left to dry for a few days. A parallel sample was prepared for carbon 
coating. When the samples had dried, they were observed under FEG-SEM using a 
voltage of 5 kV and an aperture of 20. Images were obtained with a 50 000x 
magnification.  
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7. RESULTS AND DISCUSSION 
7.1. Particle size, zeta potential and PDI 
7.1.1. Particle size  
Particle size was measured using DLS. Figure 7.1 illustrates the mean particle diameter 
of the formed chitosan-pDNA nanoparticles using different chitosans. Numerical details 
concerning size and deviations in size are presented in Appendix 1.  
 
Figure 7.1. Particle size of chitosan-pDNA nanoparticles measured by DLS on a 
logarithmic scale. Chitosan base samples with a Mw of 25 kDa, 50 kDa and 300 kDa 
are illustrated by vertical lines, light gray and horizontal lines, respectively. Other 
bases are coloured in dark gray, and chitosan salts and derivatives are plain. Sample 
names are given in the form DD/Mw. Sample specifications can be found in Appendix 1.   
 
Particle size generally ranged from 100 to 180 nm. Smallest particles were obtained 
using chitosan hydrochloride (CH HCl) and chitosan 85/25. The average size of these 
particles was 100.3 nm (std 1.3 nm) and 101.9 nm (std 0.9 nm), respectively. However, 
two of the tested chitosans did not yield nanoparticles at all. These included chitosan 
oligosaccharide (CH oligo) and carboxymethylchitosan (CMCH). This might be 
explained by the film-forming capacity of CMCH and the very small molecular weight 
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(1.5 kDa) of chitosan oligosaccharide.  At least at this solution concentration, it appears 
that the chitosan oligomers were not able to make complexes with pDNA, which may 
be due to, for instance, short chain lengths. According to theory, chitosan 
oligosaccharide can be used to prepare high concentration solutions with low viscosity 
[122]. Therefore, it is highly likely that the used preparation parameters were not 
optimal. Particle formation of CMCH, on the other hand, was perhaps hindered by 
carboxymethylation of chitosan and reduction of amino groups.  
Particle size distributions were observed to evaluate the possible aggregation of 
samples and also the reliability of the results. Figure 7.2 shows the intensity 
distributions for samples 85/25 and CH HCl. The intensity and volume distributions for 
all nanoparticles over a period of 2 weeks are presented in Appendix 2. As can be seen 
from the graphs, the intensity distributions are generally more stable and normally 
distributed than their respective volume distributions. Therefore, it is likely that 
different size complexes exist. This may be due to particle aggregation. CH oligo and 
CMCH did not yield stable distribution curves, which is why these results should be 
regarded with some scepticism.  
 
Figure 7.2. Size distributions of a) chitosan 85/25 and b) chitosan hydrochloride (CH 
HCl). 
 
The effect of pH on particle formation was assessed for chitosan acetate and 
chitosan lactate. Trials were made with both pH-adjusted (~5.5) and non-adjusted 
sample solutions. Table 7.1 presents the effect of pH on size, size stability, and zeta 
potential of nanoparticles.  
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Table 7.1. Effect of pH on particle properties. 
Chitosan pH Size (nm) StD0 
Size  
week 1 Std1 
Size 
week 2 Std2 
Zeta0 
(mV) 
Std 
zeta 
Chitosan 
acetate 
5.6 158 1.3 168.4 2.3 170.5 1.9 26 1.9 
6.7 202.4 3.1 231.3 42.9 201.7 4.1 11 0.8 
Chitosan 
lactate 
5.6 147 1.3 158.6 2.1 158.2 1.7 28 0.7 
6.7 1352 960.3 - - - - 10.5 1.2 
 
As can be observed from Table 7.1, non-pH-adjusted chitosans yielded larger 
particles with a significantly smaller zeta potential compared to the pH-adjusted 
chitosan solution. Especially chitosan lactate appeared to be affected by the initial pH 
6.7 and nanoscale particles were not achieved. Although non-pH-adjusted chitosan 
acetate formed approximately 40 nm bigger particles than the pH-adjusted version, the 
particles were still in nanoscale (~200 nm) and managed to retain a somewhat stable 
size during a period of 3 weeks.  
7.1.2. Particle size stability 
Follow-up size measurements were performed at week 1 and week 2 after particle 
preparation. The nanoparticle solutions were also observed for any changes in clarity 
due to aggregation. Appendix 3 shows the size development of nanoparticles prepared 
by different chitosans during a period of 2 weeks. As can be seen from the graphs, there 
is a slight increasing trend in size. However, by pure observation it is questionable 
whether this increase is significant as the results generally appear to fall within the 
standard deviation range. Therefore, the Mann-Whitney U test and the Student’s t-test 
(two-tailed, p < 0.05) were applied to assess the statistical significance of size stability 
using equations 11 and 12 provided in Section 5.4. Values of p < 0.05 were considered 
significant.  
Appendix 4 summarises the statistical significance of size development during a 
period of 2 weeks. From the tables it can be concluded that the parametric and non-
parametric tests generally support each other, with the exception of chitosan lactate 
whose size development is considered significant from week 0 to 1 by the Mann-
Whitney U test and non-significant by the Student’s t-test. Nevertheless, the statistical 
analysis shows that the particle size generally increased significantly from week 0 to 
week 1. The increase in size from week 0 to week 2 was also statistically significant for 
nearly all samples. The size development from week 1 to week 2, on the other hand, 
was not as significant, and only 8 out of 17 samples experienced a statistically 
significant increase in size. Therefore, it could be argued that the particle size stabilises 
after one week of preparation. 
The greatest numerical change in size was achieved by the low molecular weight 
(25 kDa) chitosans with higher DD (85 and 95). The size development of these 
chitosans is presented in Figure 7.3.  
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Figure 7.3. Development of particle size in relation to DD over a period of 2 weeks. It 
appears that higher DD with low Mw seems to have a strong impact on particle size 
stability. 
 
As can be noted from Figure 7.3, the size of sample 95/25 increased by 
approximately 45 nm and the size of sample 85/25 by about 20 nm. From this it can be 
concluded that low molecular weight chitosan bases with a high DD are more unstable 
concerning size stability. It should also be noted that CH HCl (95/40) increased in size 
with approximately 10 nm during a period of 2 weeks. As a whole, this is quite a small 
change and it is also less than the size change for low Mw and high DD chitosan bases. 
This may be due to the slightly higher molecular weight of CH HCl or to the chemical 
nature of chitosan hydrochloride.  
In general, the size of chitosan-pDNA nanoparticles first increased significantly 
during the first week after preparation and then remained relatively stable for the next 
week. Although size development was statistically significant especially during the first 
follow-up week, it may be argued that this statistical significance is not so important, as 
numerically only small changes in particle size were noted. In addition, many of the 
obtained values for the follow-up period lie within the standard deviations of 
measurements. No changes in solution clarity could be detected by the human eye. 
7.1.3. Zeta potential 
Zeta potential generally varied from approximately +20 mV to +30mV, which is in 
accordance with values presented in the literature. Figure 7.4 illustrates the zeta 
potentials of different nanoparticles.   
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Figure 7.4. Zeta potential of chitosan-pDNA nanoparticles. 
 
Greatest zeta potentials were obtained with high DD high Mw chitosan base samples 
(90/460, 95/300, 85/300, 95/150, 85/150). Zeta potentials of chitosan salts and 
derivatives were comparable to those of low DD and low Mw chitosan base samples. A 
slight correlation was observed between DD and zeta potential for chitosan base with 
Mw 150 and 300 kDa. Zeta potential appeared to increase with increased DD as Mw 
remained constant. However, measurements do express some deviation, which makes 
drawing conclusions complicated. In many cases, the particle concentration was also too 
low for reliable zeta potential measurements. Nevertheless, it is likely that high DD 
enables a higher amount of protonated amino groups in the chitosan thereby making the 
complex more stable. Naturally, a high Mw also provides a greater range for 
deacetylated units. This is in accordance with theory [37]. It should also be noted that in 
addition to DD and Mw, also pH has an important effect on zeta potential. In this study, 
the zeta potential was assessed only at pH 5.5.  
Like in most of the other measurements, the values of CMCH and CH oligo differed 
from the other samples. In this case, the values were negative. Zeta potential of CMCH 
and CH oligo was about -30 mV and -15 mV, respectively. Therefore, zeta potentials 
obtained for these samples indicate instability. As a whole, however, zeta potentials of 
chitosan samples were relatively stable and in accordance with previously presented 
values.  
7.1.4. PDI 
The polydispersity index of the chitosan nanoparticles was generally in accordance with 
values presented in the literature. Theoretical values range from 0.027 to 0.6. In this 
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study, values from 0.14 to 0.25 were obtained, excluding the values for CMCH and CH 
oligo, which were unreliable. Figure 7.5 presents the polydispersity indices for different 
samples.  
 
Figure 7.5. Polydispersity index of chitosan-pDNA nanoparticles. 
 
Most values were located between 0.14 and 0.25. Comparing the PDI with size 
volume distributions, it seems that the smaller the PDI, the less polydisperse the sample.  
7.1.5. Correlations: size and Mw, size and DD, size and ZP 
It was attempted to evaluate whether some correlation existed between different 
chitosan properties and chitosan-pDNA nanoparticle parameters. Unfortunately, no 
clear correlations were detected. Considering chitosan bases, it appears that with a DD 
of 75, the particle size increases with increasing Mw. Samples with a DD of 85 and 95, 
on the other hand, first increased in size when Mw was increased from 25 kDa to 150 
kDa. However, when the Mw was further increased to 300 kDa, the particle size 
decreased. This suggests that for high DD chitosans, either a low or high Mw is more 
suitable to yield small nanoparticles than medium molecular weight chitosan. In the 
case of DD 85, the smallest Mw produced the smallest particles, while the high 
molecular weight chitosan of DD 95 produced slightly smaller particles than the 
respective LMW chitosan. Figure 7.6 demonstrates the particle size and zeta potential as 
a function of Mw with constant DD. 
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Figure 7.6. Particle size and zeta potential as a function of Mw with constant DD. 
 
Interestingly, considering the chitosan bases with respect to the DD with constant 
Mw, it appears that the size of HMWC will decrease as a function of increased DD. 
With LMWC and MMWC this relationship was not evident. Figure 7.7 illustrates the 
particle size and zeta potential as a function of DD with constant Mw.  In the literature, 
it has been presented that particle size decreases with decreasing Mw or possibly 
increases with very small Mw if the DD remains constant. Therefore, the results of this 
study are in accordance with literature. In addition, they demonstrate that high DD and 
high Mw chitosans can yield smaller particles than high DD medium molecular weight 
chitosans.  
 
Figure 7.7. Particle size and zeta potential as a function of DD with constant Mw. 
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Zeta potential did not directly correspond to particle size, but it was mentioned 
earlier that high DD and high Mw chitosans produced the most stable complexes.  
7.2. Agarose gel electrophoresis 
Agarose gel electrophoresis illustrated that pDNA coupled with most chitosans, 
excluding carboxymethylchitosan (CMCH) and chitosan oligosaccharide (CH oligo) 
that migrated on the gel (see Figure 7.8).   
 
 
Figure 7.8. Agarose gel electrophoresis image. From left to right: DNA ladder, 
plasmid, 75/50, 85/50, 95/50, CMCH, CH oligo and CH HCl. 
 
A more extensive gel electrophoresis image collage is given in Appendix 5. Possible 
explanations for the failure of chitosan oligosaccharide and carboxymethylchitosan to 
integrate plasmid DNA include the inability to form particles due to, for instance, low 
molecular weight (CH oligo) and the lack of an appropriate amount of amino groups 
(CMCH). Based on the gel electrophoresis images, it is likely that the pDNA resided 
free in the solution. CH oligo and CMCH –pDNA nanoparticles could be prepared with 
different chitosan:pDNA weight ratios in order to assess whether this would yield 
nanoparticles.  
7.3. FEG-SEM 
FEG-SEM images were obtained for chitosan 85/25-, 80/250- and chitosan 
hydrochloride pDNA nanoparticles. Carbon-coated samples produced better quality 
images. Some images are shown in Figure 7.9. 
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Figure 7.9. FEG-SEM images of chitosan-pDNA nanoparticles. Nanoparticles were 
prepares using a) CH HCl b) 85/25 and c and d) 80/250. Magnifications are 50 000x 
(a-c) and 100x (d).  
 
As can be seen from Figure 7.9a, chitosan HCl yielded relatively uniform and 
numerous nanoparticles. Some particles appeared sphere-like, while some resembled 
flakes. Also 85/25 produced sphere-like particles, though these were not as evenly 
spread and numerous as CH HCl. Some of the particles in the 100 nm range of 85/25 
seemed slightly raisin-like and not as spherical (see Figure 7.9b). This could be 
explained by aggregation of smaller particles. Another possible explanation may be the 
hydrogel nature of chitosan-pDNA nanoparticles. In a solution, the shape may be more 
spherical due to swelling. However, the latter is subject to contradiction as previous 
studies [43; 59; 74] have demonstrated spherical structures for chitosan-pDNA 
nanoparticles. Nevertheless, this explanation could be verified by observing the particles 
by AFM, which allows imaging in aqueous conditions and thus, the real environment of 
the particles.  
The particle yield of the reference chitosan, 80/250, was surprisingly low compared 
to previous studies using the same parameters (Figure 7.9c). The reference particles also 
appeared to produce raisin-like structures. Nevertheless, while the particle size was 
quite small (~20 nm) the particles were relatively spherical. In the case of bigger 
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particles (100-200 nm), the raisin-like structures persisted, which suggests aggregation. 
The raisin-like structures of sample 80/250 and 85/25 are shown in Figure 7.10.  
 
 
Figure 7.10. a) Chitosan-pDNA nanoparticles prepared using chitosan 80/250 and b) 
85/25. 
 
Although particles were not as spherical and uniformly distributed as desired, FEG-
SEM images supported the nanoscale size measurements of DLS. In fact, particles were 
even smaller than in DLS measurements, probably due to drying. Some possible sources 
for error in FEG-SEM imaging may include the arbitrary image spot on the grid, 
disturbances in carbon coating and technical problems with the FEG-SEM. Indeed, 
there were some issues with the focus of the FEG-SEM, and it was suggested that 
perhaps there is a disturbance in the microscope column. However, changing the 
aperture from 30 to 20 made imaging possible, though close-ups did not succeed. 
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8. CONCLUSIONS 
The objective of this study was to prepare and characterise chitosan-pDNA 
nanoparticles using 17 different types of chitosan in order to assess which chitosan 
yields the most favourable nanoparticle characteristics in terms of size, size stability and 
zeta potential. Also possible correlations between chitosan properties like DD, Mw, and 
particle parameters were explored. Both chitosan bases and water-soluble chitosan salts 
and derivatives were tested.  
Chitosan-pDNA nanoparticles were successfully prepared by complex coacervation 
with a fixed chitosan to pDNA weight ratio of 4:1. Only two chitosans, including 
chitosan oligosaccharide and carboxymethylchitosan, did not form nanoparticles at this 
ratio. The remaining chitosans, however, formed particles with sizes ranging from 100 
to 180 nm. Also the zeta potential of these chitosans was relatively stable and ranged 
from +20 to +30 mV. Particle size and zeta potential was assessed by dynamic light 
scattering and laser Doppler velocimetry, respectively. Integration of pDNA to the 
particles was evaluated using gel electrophoresis and finally the morphology of the most 
prominent samples, including chitosan base 85/25 and chitosan hydrochloride, was 
observed under FEG-SEM. The combination of the mentioned characterisation 
techniques appeared successful as results supported each other. For example, CH oligo 
and CMCH that did not form particles according to DLS expectedly migrated during gel 
electrophoresis, unlike other samples. Moreover, the zeta potential of CH oligo and 
CMCH was negative, which differed from other samples. The underlying reasons for 
the unsuccessful results for CH oligo and CMCH may be explained by the chemical 
nature of these materials. For instance, the molecular weight of CH oligo at the given 
preparation parameters may simply be too low to produce nanoparticles. Moreover, the 
chemical properties of CMCH may significantly affect particle formation. For example, 
N,O-carboxymethylchitosan has a reduced amount of protonated amino groups due to 
N-carboxymethylation. Particle formation based on electrostatic interaction may 
therefore be hindered.  
Unfortunately, no clear correlations between chitosan properties and chitosan-
pDNA nanoparticle properties were found. However, it would seem that a higher DD 
and Mw lead to more stable particles, as the zeta potential is increased due to an elevated 
number of protonated amino groups. It appears that for low DD (75%) chitosans, an 
increase in Mw leads to an increase in particle size. For higher DDs, this relationship 
was not evident.  In fact, particle size first increased when the Mw was increased from 
25 kDa to 150 kDa. Thereafter, particle size decreased when the Mw was further 
increased to 300 kDa with a constant DD. Size stability experienced a slight increasing 
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trend over a period of 2 weeks. Statistical analysis indicated that for most samples 
particle size increased significantly during the first week and then remained relatively 
stable. Low Mw chitosan bases with high DD (85/25 and 95/25) seemed to experience 
the greatest increase in size ranging from 20-40 nm. Therefore, these chitosans should 
be used with care in cases where size stability is of utmost importance.   
FEG-SEM was a useful tool for particle visualisation. Unfortunately, some technical 
problems were encountered during the use of SEM and also an inexplicable black 
membrane covered the sample grid. Nevertheless, particles were detected despite the 
fact that close-ups could not be obtained due to a lower aperture. According to FEG-
SEM, particle size ranged from approximately 20 to 200 nm. Smaller particles appeared 
more uniform and spherical in size than bigger complexes that appeared raisin-like. This 
suggests that some aggregation is present. Alternatively, the particles may possess a 
hydrogel nature which diminishes when the sample is dried, resulting in “shrunken” 
complexes. AFM, that allows observation of particles in aqueous media, may be a 
useful imaging technique to assess the latter, as it better reflects the true environment of 
nanoparticles. Chitosan hydrochloride appeared to produce more numerous and uniform 
particles than chitosan base 85/25. Therefore, the choice between a chitosan base and a 
chitosan derivative seems insignificant, though it should be verified that the chosen 
derivative or salt actually yields nanoparticles at a given chitosan to pDNA weight ratio.  
As a whole, most samples (15/17) yielded acceptable results in terms of size, size 
stability and zeta potential. Only chitosan oligosaccharide and carboxymethylchitosan 
displayed unsatisfactory results at the given preparation parameters. As the chemical 
nature of chitosan and especially chitosan derivatives may vary significantly, it is 
perhaps somewhat naive to believe that the best results would be obtained at a fixed 
chitosan to pDNA ratio for all samples. Therefore, future experiments should focus on 
exploring the effects of different chitosan:pDNA weight ratios on particle parameters. 
Also the possibility to functionalise the prepared samples should be explored. Although 
chitosan 85/25 and chitosan HCl produced the smallest particles at the given weight 
ratio, it was observed by other researchers in the same project that functionalisation of 
these particles was unachievable due to sedimentation. However, when the weight ratio 
was changed, functionalisation properties were improved. Only after careful 
consideration of all parameters should the most prominent samples be tested in vitro and 
finally in vivo. Also other factors such as cost, time, manufacturability and sterilisation 
properties should be considered. In addition, different preparation techniques, such as a 
recently introduced osmosis-based method, could be explored.  
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Mann-Whitney U, p < 0.05 is significant Student's t-test, p < 0.05, df 16, two-tailed 95%, t = 2.120 
Sample Week 0-1 Week 1-2 Week 0-2 Week 0-1 Week 1-2 Week 0-2 
80/250 S NS S S NS S 
90/460 S S S S S S 
CH glut  S NS S S NS S 
75/25 S NS NS S NS NS 
85/25 S S S S S S 
95/25 S S S S S S 
75/300 S NS S S NS S 
85/300 S NS S S NS S 
95/300 S S S S S S 
75/150 S S S S S S 
85/150 S NS S S NS S 
95/150 S NS S S NS S 
CMCH S S S S S S 
CH oligo  S S S S S S 
CH HCl S S S S S S 
CH ace S NS S S NS S 
CH ace pH 
6.7 NS NS NS NS NS NS 
CH lac S NS S NS NS S 
Student's t-test values, p < 0.05, df 16, two-
tailed 95%, t = 2.120 
*absolute values were used when 
assessing significance  
Sample 
Week 0-
1* 
Week 1-
2* 
Week 0-
2* S = significant change 
80/250 -7.602 0.552 -10.017 NS = non-significant 
90/460 -7.768 -2.618 -7.056 df = degrees of freedom 
CH glut  -3.519 -1.085 -4.634 
75/25 -2.180 1.776 -0.474 
85/25 -29.586 -13.126 -35.696 
95/25 -34.577 -14.191 -47.205 
75/300 -4.918 0.905 -4.072 
85/300 -6.267 -1.564 -6.498 
95/300 -7.328 -2.789 -12.748 
75/150 -6.585 -3.534 -8.106 
85/150 -7.189 -1.297 -8.029 
95/150 23.682 46.476 46.833 
CMCH 12.281 -8.880 2.990 
CH oligo  3.198 4.199 10.966 
CH HCl -9.086 -4.815 -14.208 
CH ace -11.583 -2.102 -16.179 
CH ace pH 
6.7 -2.015 2.060 0.409 
CH lac -1.855 1.842 -15.525 
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